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This dissertation studies the structures and functions of novel signaling regulators, 
with Chapter 2-4 focusing on sirtuins and Chapter 5 on the DOCK180 family of Rho 
GEFs. Sirtuins are NAD-dependent deacetylases that regulate important biological 
processes. Mammals have seven sirtuins, SIRT1-7. SIRT4-7 have undetectable or 
weak deacetylase activity. In Chapter 2 we identified SIRT5 as an efficient protein 
lysine desuccinylase and demalonylase. The preference for succinyl and malonyl 
groups is accomplished by their interactions with residue Tyr102 and Arg105 of 
SIRT5. Lysine malonylation and succinylation were identified in mammalian proteins. 
Additionally, SIRT5 can reverse succinylation in vivo. In Chapter 3 I delineated the 
desuccinylation reaction of SIRT5 in crystals, including the complex structure of 
SIRT5 with a bicyclic intermediate. The SIRT5 complex structures will provide 
insights to the design of SIRT5-specific inhibitors to investigate its biological 
functions. In Chapter 4, we investigated a sirtuin homologue from the malaria parasite 
Plasmodium falciparum, PfSir2A, which regulates the expression of surface antigens 
to evade the detection by host immune surveillance. We present enzymology and 
structural evidence supporting that PfSir2A preferentially hydrolyzes medium and 
long chain fatty acyl groups from lysine residues. This would facilitate the 
 development of PfSir2A inhibitors as potential drugs in malaria treatment. 
As the Guanine nucleotide Exchange Factors (GEFs) of Rho GTPases, the 
DOCK180 family proteins are key regulators of cell motility, phagocytosis, and 
adhesion. Mammals have 11 members, DOCK1-11, which are classified into four 
subfamilies, A through D. The DOCK-C subfamily that includes DOCK6-8 has been 
proposed to activate both Cdc42 and Rac1. In Chapter 5 I show that DOCK7 promotes 
very weak activation of non-prenylated Cdc42 or Rac1 in solution, but robust 
activation of prenylated Cdc42 and Rac1 on model liposomes, demonstrating that the 
prenylation and membrane localization of GTPases are essential for the activation by 
DOCK7. Additionally, DOCK7 harbors residues that impart GTPase specificity and 
these can be mutated to shift a given DOCK7 activity profile. Finally, the DOCK7 
possesses a distal site that binds preferentially to the active forms of Cdc42 and Rac1 
and thereby forms a possible positive feedback loop in activating GTPases.  
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Chapter 1   Introduction 
1.1 Sirtuins 
The History and Characteristics of Sirtuins  
Sirtuins are named after its founding member Sir2, short for silent information 
regulator 2, that was discovered in yeast about two decades ago (1, 2). Sir2 was 
originally found to suppress the recombination of ribosomal RNA as well as to silence 
the genes near the telomere (1). In 1995, Brachman et al. discovered four additional 
homologues of Sir2 in yeast, Hst (homologues of Sir2) 1-4, which were all associated 
with gene silencing, cell cycle progression, and genomic stability. The discovery of 
Sir2 homologues in yeast led to the finding that sirtuins were conserved in every 
domain of life, from bacteria to mammals (3). Mammals have seven sirtuins: SIRT1-7, 
which have attracted increasing attention because of their profound roles in human 
health and diseases (2).  
One significant characteristic of the sirtuin proteins is that they all have a 
highly conserved catalytic domain of about 275 amino acids and variant N- and/or C- 
termini of different lengths. According to the phylogenetic analysis of the catalytic 
domains from more than 60 sirtuins, ranging from prokaryotes to eukaryotes, sirtuins 
were classified into five classes: class I-IV and Class U. All the yeast sirtuins fall into 
Class I which also includes mammalian SIRT1-3 as well as at least one Sir2 
homologue from most eukaryotes. Class II sirtuins come from various organisms, 
ranging from bacteria, to insects, nematodes, fungus and protozoans. Mammalian 
SIRT4 is a member of Class II sirtuins. Sirtuins from prokaryotes form the majority of 
Class III, with SIRT5 as a mammalian member. All Class IV members are from 
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eukaryotes, including mammalian SIRT6 and SIRT7. Class U contains those sirtuins 
which do not belong to Classes I-IV (4).  
 The unique variable N- and/or C- termini of sirtuins determine their sub-
cellular localization. Yeast Sir2 was discovered to localize to the nucleolus where 
DNA-breaks reside (5). The seven mammalian sirtuins differ in their localizations 
(Table 1.1). SIRT1, SIRT6, and SIRT7 reside in the nucleus. Specifically, most SIRT1 
is associated with euchromatin while SIRT6 is associated with heterochromatin, and 
SIRT7 localizes in the nucleolus. SIRT2 predominantly distributes in the cytoplasm. 
SIRT3-5 have been found in the mitochondria (6). Their different sub-cellular 
localizations are the major determinants of their cellular functions. 
 
Sirtuins Are NAD-dependent ADP-ribosyltransferases, Deacetylases, 
Depropoinylases, and Debutyrylases. 
Sirtuin was initially found as an NAD-dependent ADP-ribosyl transferase 
which transfers a single ADP-ribose from NAD to an arginine or lysine residue of a 
substrate protein. In 1999, Roy Frye discovered that human SIRT2 was able to transfer 
a mono-ADP ribose to BSA (7). The yeast Sir2 was then reported to ADP-ribosylate 
itself and histones, while a histidine to tyrosine mutation abolished its ADP-
ribosylation activity (8). This led to the thought that the ADP-ribosylation activity of 
Sir2 was related to the output of gene silencing. In 2005, the mouse SIRT6 protein was 
shown to be self-ADP-ribosylated (9). In 2006, Haigis et al. demonstrated that mouse 
SIRT4 could downregulate the activity of glutamate dehydrogenase (GDH) by 
catalyzing its ADP-ribosylation, thereby suppressing insulin secretion (10). However,  
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Table 1.1. Summary of the seven mammalian sirtuins. 
 
  Deacetylation activity  Deacetylation substrates 
SIRT1 nucleus robust 
FOXO134, FOXO3a22, FOXO422, H1K2631, 
H3K913, H3K1413, H4K1613, Ku7036, 
p300/CBP21, p5320, PCAF, PGC-1α24, 
TAFI6823, AceCS1/248, HMGCS1/248 
SIRT2 cytoplasm robust α-tubulin
16, FOXO133, FOXO3a33, H3K1413, 
H4K1613, p5339, p30032 
SIRT3 mitochondrion robust AceCS2
17, H4K16, p5340, ICDH218, GDH18, 
LCAD42, HMGCS248 
SIRT4 mitochondrion none none 
SIRT5 mitochondrion weak Cytochrome C18, CPS183 
SIRT6 nucleus weak H3K919, H3K5636, CtIP38 
SIRT7 nucleolus none none 
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recent studies suggested that the ADP-ribosylation activity of sirtuins was so low that 
it might be physiologically irrelevant (11, 12). Soon after the discovery of ADP-
ribosylation, sirtuins were identified as NAD-dependent deacetylases, although 
distinct from the family of histone deacetylases (HDACs). Yeast Sir2 could 
deacetylate histone 3 at lysine residues 9 and 14, as well as histone 4 at lysine residues 
5, 8 and 16, causing a decrease in the global acetylation levels of histones. This led to 
the conclusion that deacetylation rather than ADP-ribosylation catalyzed by sirtuins 
was essential for gene silencing and rDNA recombination (13, 14). The in vitro NAD-
dependent deacetylation activity was described for a number of other sirtuins, 
including yeast Hst2, bacterial CobB from Salmonella typhinurium, archaebacterial 
Sir2Af from Archaeoglobus fulgidus, and human SIRT1-3, SIRT5 and SIRT6 (15-19). 
Extensive studies have shown that the sirtuin substrates are not limited to histones. For 
example, human SIRT1 could deacetylate diverse substrates, including the tumor 
suppressor p53, the histone acetyltransferase p300, the transcriptional factors FOXO 
proteins, NF-κB, and PGC-1α (20-24). To date, most biological functions of sirtuins 
have been assigned to their deacetylation activity.  
 Recently, a few sirtuins have been demonstrated to show depropionylation 
and/or debutyrylation activities (25-29). Human SIRT2 and yeast Hst2 showed 
moderate depropionylation and little debutyrylation on histone peptides, compared to 
their robust deacetylation activity (25). The findings of the depropionylation and 
debutyrylation of sirtuins were coupled by the identification of two novel 
posttranslational modifications: lysine propionylation and butyrylation on some 
proteins, including histones, propionyl-CoA synthetase, and p53 (28, 30). The 
discovery of those new activities of sirtuins not only extends their physiological roles, 
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but also builds a broader perspective on the substrates and biochemical functions of 
sirtuins. Sirtuins with little or no deacetylation activity might function to remove other 
acyl groups from substrate lysine residues. 
 
Cellular Functions of Sirtuins:  
• Transcriptional Regulation  
Histone acetylation is associated with active gene transcription by relaxing the 
condensed chromatin DNA. sirtuins were found to negatively regulate gene expression 
by deacetylating histones at some specific lysine positions, including positions 9 and 
26 of H1, 9 and 14 of H3, and 16 of H4 (13, 31). Human SIRT1 can deacetylate the 
histone acetyltransferase p300 at Lys1020 and Lys1024 within the cell cycle 
regulatory domain 1 (CRD1 domain), therein repressing p300-mediated transcriptional 
activity (21). SIRT2 can also deacetylate p300 within the catalytic histone 
acetyltransferase (HAT) domain (32). 
The FOXO proteins, the class O of forkhead box members, are a family of 
transcriptional factors that play pivotal roles in the regulation of genes involved in 
apoptosis, metabolism, and longevity. SIRT1 was demonstrated to deacetylate FOXO3 
under oxidative stress, therein enhancing the expression of target genes in cell cycle 
arrest and stress resistance, while reducing the expression of those genes involved in 
apoptosis (22). In another study, SIRT2 was reported to deacetylate FOXO1 in 
adipocytes and promote its binding to PPARγ, decreasing PPARγ’s transcriptional 
activity (33). FOXO1 can also be deacetylated by SIRT1, which inhibits FOXO1-
mediated gene transcription (34).  
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• DNA Repair and Genomic Stability  
Tsukamoto et al. found that yeast Sir2, forming a complex with Sir3 and Sir4, 
interacted with yeast Ku proteins and promoted the double-strand break (DSB) repair 
pathway via non-homologous end joining (NHEJ) (5). The yeast Sir2 homologues, 
Hst1-4, were also involved in DNA repair and genomic stability. Hst3/Hst4 double 
mutants displayed low viability and increased chromosome loss (3). Further study 
elucidated that Hst3 and Hst4 controlled DNA repair and genome integrity by 
deacetylating histone 3 at lysine 56 during the G2/M phase of the cell cycle (35).  
Human SIRT1 was also found to deacetylate Ku70 protein under the stress of 
ionizing radiation (IR), thereby activating the DSB repair pathway (36). Another 
nuclear sirtuin SIRT6 in mammals also played a crucial role in preserving genomic 
stability and promoting DNA repair. SIRT6-deficient cells became notably more 
sensitive to DNA-damage agents, and showed accumulation of fragmented 
chromosomes, detached centromeres, and gaps, which was caused by the inactivation 
of base excision repair (BER) mediated by SIRT6 (37). Additionally, SIRT6 was 
identified as a Histone 3 lysine 9 deacetylase and to be involved in the regulation of 
telomere maintenance. Further study demonstrated that SIRT6 could deacetylate 
histone 3 at lysine 56, which linked SIRT6 to telomeric DNA repair (19). Recently, 
SIRT6 was reported to interact and deacetylate CtIP [C-terminal Binding Protein 
(CtBP) Interacting Protein], a DSB resection protein, indicating that SIRT6 is pivotal 
in DNA damage repair and in the preservation of genomic integrity (38).  
• Cell Survival and Apoptosis  
Sirtuins have been implicated in various cancers, thanks to their suppression of 
apoptosis and promotion of cell survival. Among all the seven mammalian sirtuins, 
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SIRT1-3 have been especially well studied with regard to their roles in cancer 
development. SIRT1-3 can deacetylate and downregulate the transactivation activity 
of the tumor suppressor p53, causing cells to bypass p53-dependent apoptosis under 
stress (20, 39, 40). SIRT1-deficient mice showed developmental defects and usually 
died shortly after birth. The SIRT1-deficient MEFs exhibited p53 hyperacetylation 
when exposed to DNA damage agents (41). SIRT2 was shown to interact with 14-3-3 
β/γ which enhanced the deacetylation of p53 by SIRT2 in an AKT-dependent way 
(39). The p53 protein was recently identified as a SIRT3 substrate, and SIRT3 
overexpression could rescue the p53-dependent cell cycle arrest (40). As mentioned 
above, SIRT1 can deacetylate FOXO3, which represses FOXO3’s capability to induce 
cell death, thereby promoting cell survival (22).  
• Metabolism 
Mitochondria are the energy machinery of cells. In mammals, three sirtuins, 
SIRT3-5, predominantly reside in the mitochondria, which play important roles in 
regulating metabolism in response to nutrient changes. Acetyl-CoA synthetase 2 
(AceCS2), the first SIRT3 substrate to be identified, is deacetyated and activated by 
SIRT3, thereby producing more acetyl-CoA for energy production in the citric acid 
cycle (17). SIRT3 has been found in vitro to deacetylate and activate isocitrate 
dehydrogenase 2 (ICDH2) which generates a key molecule, α-ketoglutarate, in the 
citric acid cycle. In the same study, SIRT3 was demonstrated to deacetylate and 
activate glutamate dehydrogenase (GDH) which converts glutamate to α-ketoglutarate 
for ATP production and plays a crucial role in the citric acid and urea cycles (18). 
Recently, long-chain acyl CoA dehydrogenase (LCAD) has been identified as a SIRT3 
deacetylation target, indicating that SIRT3 is pivotal for regulating fatty-acid oxidation 
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(42). SIRT3 can deacetylate 3-hydroxyl-3-methylglutary-CoA synthetase 2 
(HMGCS2) on the three lysines within its active site, and enhances HMGCS2 
enzymatic activity under fasting conditions, thereby increasing the production of 
ketone bodies for direct use as an energy source in some tissues (43). Several research 
groups have shown that SIRT3 interacts with and deacetylates the mitochondrial 
respiration complex I-V in the electron transport chain, suggesting that SIRT3 helps 
regulate ATP homeostasis (44-47). However, opposite to SIRT3, SIRT4 has been 
reported to ADP ribosylate GDH and downregulate its activity, which inhibits ATP 
production and insulin secretion in pancreatic β cells (10).  
Similar to SIRT3, SIRT1 has been shown to deacetylate and activate AceCS1, 
2 and HMGCS1, 2, with AceCS1, HMGCS1 as the cytoplasmic homologues of 
mitochondrial AceCS2 and HMGCS2, respectively, directly linking SIRT1 to the 
citric acid cycle and fatty-acid oxidation for ATP generation (48). Additionally, SIRT1 
can interact with and deacetylate the transcriptional coactivator PGC-1α, through 
which SIRT1 controls glucose homeostasis via the glycolytic pathway in response to 
fasting (24). 
• Neurodegeneration and Neuroprotection 
Sirtuins play important roles in neurodeneration and neuroprotection, as some 
sirtuins are highly expressed in the nervous system, including SIRT1 and SIRT2 (6). 
SIRT1 was highly expressed in neuronal bodies while SIRT2 was enriched in 
oligodendrocytes and in the Schwann cells of axons (49). Qin et al. found that SIRT1 
prevented amyloid β peptide formation in Alzheimer disease in response to calorie 
restriction by suppressing the Rho-associated kinase ROCK1-mediated inhibition of α-
secretase which produces the non-toxic α-amyloid instead of the pathogenic β-amyloid 
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peptide (50). SIRT2 deacetylates α-tubulin which is the key component of 
microtubules, suggesting that SIRT2 is pivotal in the modulation of neuronal 
differentiation and migration (16). The mechanism of sirtuin’s neurodegenerative and 
neuroprotective is still unclear.   
Sirtuins have been appreciated for their role in lifespan extension. 
Overexpression of Sir2 can extend the lifespan of yeast and worms under conditions of 
calorie restriction (51, 52). This beneficiary effect of lifespan extension under calorie 
restriction was also found in other organisms, including fruit flies, spiders, and rodents 
(53-55). Sirtuins are also involved in some age-associated diseases, such as metabolic 
disease (56, 57), Alzheimer’s disease (50, 58, 59), Parkinson’s disease (60, 61), and 
cancer (62-65). 
 
The Deacetylation Mechanism of Sirtuins and Substrate Specificity 
 In the presence of NAD, sirtuins transfer the acetyl group from an acetylated 
substrate protein/peptide to the ADP-ribose portion of NAD, and produce 
nicotinamide, a deacetylated protein/peptide, and a novel molecule, O-acetyl-ADP-
ribose (OAADPRr) (66-68). The two substrates, acetylated protein and NAD, bind to 
the active site of sirtuins in an ordered manner: the acetylated protein binds first, 
followed by the binding of NAD. Nicotinamide is then released. The deacetylated 
protein and OAADPr are released randomly when the reaction is completed (69). With 
the expanding understanding of the important cellular roles of sirtuins, the importance 
of understanding the enzymatic mechanism of deacetylation becomes more obvious, to 
facilitate the design of inhibitors and activators for pharmaceutical purposes. 
Extensive biochemical and structural studies have been conducted to elucidate the 
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enzymatic mechanism. Three alternatives have been proposed: the nucleophilic attack 
mechanism, the enzyme nucleophile mechanism, and the ADPR-peptidyl-imidate 
mechanism, with the latter being the most widely accepted (66).  
 In the ADPR-peptidyl-imidate mechanism (Fig.1.1), upon the binding of both 
acetylated protein and NAD, the nicotinamide group from NAD is first cleaved, 
forming an oxocarbonium-ion transition state; then, the carbonyl oxygen from the 
acetylated substrate protein attacks the positively charged 1’-carbon position of the 
nicotinamide ribose, forming the ADPR-peptidyl-imidate intermediate. The ribose 2’-
OH, when deprotonated by the enzyme, attacks the amidate at the acetyl carbon, 
generating the 1’-2’-cyclic intermediate, followed by the hydrolysis of a water 
molecule, producing 2’-O-acetyl-ADP-ribose (2’- OAADPr) which can be non- 
enzymatically isomerized into 3’-OAADPr. The histidine residue that is highly 
conserved among the sirtuin family serves as a general base to deprotonate the 2’-OH 
for attacking the 1’-O-alkyl-amidate. Mutating the conserved histidine to tyrosine 
dramatically decreased the enzyme’s deacetylation activity. 
A series of structures of sirtuin complexes with either their substrate peptide or 
NAD, or both, as well as with deacetylated peptide product, have been solved 
(reviewed in 67). These structures have defined the binding sites for the two substrates 
and provided insights into the catalytic mechanism proposed above. The overall 
structure of the sirtuins is highly conserved from bacteria to human, consisting of a 
large Rossmann-fold domain characterized for NAD binding and a small zinc-binding 
domain with four invariant cysteine residues. The acetylated substrate peptide binds to 
the small cleft between the two domains and forms a β-strand with the enzyme mainly 
via backbone hydrogen bonds, causing the zinc-binding domain to rotate clockwise to  
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Figure 1.1. The deacetylation mechanism of sirtuins. Some of the oxygen atoms are 
colored differently to indicate how they originate. 
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the Rossmann-fold domain, thereby driving the enzyme from the inactive open state to 
the active close state. The acetyl lysine inserts into a hydrophobic tunnel and is 
accessible to the nicotinamide ribose of NAD for the nucleophilic attack of the 
carbonyl oxygen. Upon the binding of the acetylated substrate peptide, NAD binds to 
the enzyme in a productive position with the nicotinamide moiety inserting into the 
proposed C pocket where it is cleaved as the first step of the reaction. The invariant 
histidine residue forms hydrogen bonds with the 3’-OH of the nicotinamide ribose, 
supporting the idea that histidine acts as a base to deprotonate the 2’-OH to promote 
the nucleophilic attack.  
Previously, kinetic experiments and mass spectrometry analyses have 
confirmed the existence of the alkylamidate and the cyclic intermediates (70, 71). 
However, no direct observation has been obtained until recently when two structures 
of different sirtuins with the alkylamidate intermediate were solved and shown to 
support one of the intermediate steps. By using the mechanism-based inhibitor, 
thioacetyl lysine peptide, the S-alkylamidate intermediate was captured in the Sir2Tm 
and SIRT3 crystals (72, 73). The intermediate state aligned well with both the acetyl 
lysine peptide and NAD in a Michaelis-Menten complex, suggesting that only a small 
rearrangement was required for the removal of nicotinamide and acetyl groups. More 
sirtuin structures with the oxocarbonium ion or bicyclic intermediate bound are needed 
to address the other two intermediate steps.  
 As mentioned earlier, mammalian SIRT1 could deacetylate diverse substrates 
(20-24, 31, 34, 36, 48), which raises the question whether sirtuins have any substrate 
specificity. Not surprisingly, human SIRT1 showed no specificity for the amino acid 
sequence flanking the acetyl lysine of substrate peptides in vitro (74). However, 
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previous kinetic studies reported that yeast Sir2, Hst2, and human SIRT2 showed a 
few fold differences in either the substrate binding affinity or the catalytic efficiency 
over several mono-acetylated histone peptides (69). All the sirtuin complex structures 
with peptide bound showed that the interactions between the acetyl peptide and the 
enzyme mainly came from the backbone hydrogen bonds, with only a couple of 
hydrogen bonds from the side chains at the -1 and +2 positions (acetyl lysine at the 
position 0). Mutation of any individual residue at these two positions had only modest 
effects on the peptide binding affinity, suggesting that the side chain interactions were 
not the major contributing factors in sirtuin’s substrate recognition (75).  
 Almost all the previous studies on substrate specificity focused on the primary 
sequence proximate to the acetylated lysine of substrate peptides. Under physiological 
conditions, substrate recognition by the sirtuins may be partially determined by their 
sub-cellular localization and the sequences beyond the catalytic core of sirtuins, as 
well as by the other parts except the sequences flanking the acetyl lysine of substrate 
proteins. Recently sirtuins were found to remove propionyl and butyryl groups from 
lysine (25-29), which implied that sirtuins might exhibit their specificity, not on the 
sequence near the modified lysine, but on the modification of the lysine residues. This 
will likely attract more attention from the sirtuin research community with regard to 
understanding the properties of their substrate binding sites.   
 
Activators and Inhibitors of sirtuins 
As described above, sirtuins play important yet complex roles in human health 
and disease, which has led to increasing attention for their therapeutic potential. For 
instance, SIRT2 inhibitors have therapeutic potential in the treatment of Parkinson’s 
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disease (60). Efforts have been put forward to identify sirtuin activators and inhibitors. 
To date, a few small molecules have been reported to be effective in either elevating 
or inhibiting the activity of the sirtuins (76-80).  
Several plant polyphenols were identified by high throughput screening of a 
small molecule library. Resveratrol, commonly found in red wine, was one of those 
polyphenols which exhibited a significant activation of SIRT1 using in vitro 
fluorescent assays (76).  However, this has been controversial because no SIRT1 
activation was detected upon the addition of resveratrol when using non-fluorophore-
containing peptides (81, 82). 
A number of small molecules have been reported as sirtuin inhibitors, 
including sirtinol and suramin, but their selectivity among sirtuins requires further 
optimization (77, 78). As the first product of the sirtuin-catalyzed deacetylation 
reaction, nicotinamide is the physiological inhibitor which acts as a non-competitive 
product inhibitor to reverse the reaction and regenerate NAD (79, 80). Recently, the 
mechanism-based inhibitor, thioacetyl peptide, showed significant potential in 
inhibiting sirtuins activity by stalling the intermediate at the active site (71).  
 
During my dissertation research, I aimed to investigate those mammalian 
sirtuins that show low deacetylation activity, such as mammalian SIRT4-7, to figure 
out their biological functions and physiological substrates. In Chapter 2, I started with 
the X-ray crystal structures of SIRT5 complexed with different thioacetyl peptides, 
which showed that the primary sequences flanking the acetylated lysine did not 
influence the substrate specificity of SIRT5. Interestingly, a SIRT5 structure with a 
buffer molecule of CHES (N-cyclohexyl-2-aminoethanesulfonic acid) bound showed 
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that SIRT5 harbored an unusual lysine binding pocket with extra space to 
accommodate larger modifications and two non-hydrophobic residues, Tyr102 and 
Arg105, at the bottom of the pocket. These structural features led to the discovery of a 
novel function for SIRT5, specifically as a NAD-dependent demalonylase and 
desuccinylase. None of the other six mammalian sirtuins displayed significant 
demalonylation or desuccinylation activity. In addition, SIRT5 regulated the 
enzymatic activity of carbamoyl phosphate synthetase 1 (CPS1), a physiological 
substrate of SIRT5 (83), by desuccinylating CPS1 at lysine 1291. In Chapter 3, I 
further crystallized and solved a series of structures of SIRT5 bound with a succinyl 
peptide, or both a succinyl peptide and NAD, or a bicyclic intermediate, delineating 
the desuccinylation reaction step by step. This is the first time that a bicyclic 
intermediate was directly observed, which supports the ADPR-peptidyl-imidate 
mechanism.  
In Chapter 4, we investigated a Sir2 homologue from a parasite Plasmodium 
falciparum (P. falciparum) which is the most dangerous species of the Plasmodium 
genus that causes malaria. P. falciparum Sir2A (PfSir2A) has been shown to regulate 
the expression of surface antigens to evade the detection by host immune surveillance. 
It has been proposed that PfSir2A achieves this by deacetylating histones. However, 
PfSir2A exhibited weak deacetylation activity in previous studies (84). We 
demonstrated that PfSir2A preferentially catalyzed the hydrolysis of the medium and 
long chain fatty acyl modifications from lysine residues in vitro. In addition, medium 
and long chain fatty acyl modifications on lysine residues were shown to exist in the 
proteome of P. falciparum, and these modifications could be reversed by recombinant 
PfSir2A in vitro. The structures of PfSir2A complexed with a myristoyl peptide or 
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with both a myristoyl peptide and NAD were solved to provide a structural 
explanation as to how PfSir2A preferentially removes the medium and long chain fatty 
acyl modifications. The novel function and the crystal structures of PfSir2A may 
facilitate the development of inhibitors for treating malaria.  
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1.2. Rho GTPases and Rho GEFs of DOCK180 Family 
Rho GTPases: Functions, Posttranslational Modifications, and Regulation 
The Rho family of small GTPases, with Cdc42, Rac1, and RhoA as three 
classical members, have been initially known for their pivotal functions in regulating 
actin cytoskeleton dynamics (85, 86). For example, the hyperactivation of Cdc42 
triggers filopodia formation (87, 88), while activated Rac1 and RhoA induce the 
formation of lamellipodia and actin stress fibers, respectively (87, 89, 90). With an 
ever expanding list of downstream targets, Rho GTPases have been demonstrated to 
be essential for a wide range of cellular processes, including cell polarity, apoptosis, 
membrane trafficking, phagocytosis, cellular transformation, gene transcription, 
adhesion, and cell growth (91-93). 
Rho GTPase proteins contain a classical guanine nucleotide-binding domain 
(GTPase or G- domain), followed by a small polybasic region (PBR) and a CAAX 
motif (where C represents cysteine, A is any aliphatic amino acid, and X is any amino 
acid) at the C-terminus. To date, a number of X-ray crystal structures of Cdc42, Rac1 
and RhoA have been solved to better the understanding of the molecular basis of how 
they interact with binding partners (94-97). The G-domain, with relatively low 
intrinsic GTP hydrolytic activity, is responsible for the binding of upstream regulators 
and downstream effectors. The PBR consists of several positively charged lysine 
and/or arginine residues, which promote the association of these GTPases with 
negatively charged membranes (98). The C-terminal CAAX motif is 
posttranslationally modified by three enzymes. First, the prenyltransferase catalyzes 
the modification of CAAX motifs and covalently adds a farnesyl or geranylgeranyl 
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isoprenoid lipid tail to the cysteine residue. Cdc42, Rac1, and RhoA are all 
geranylgeranylated. Next, the Rce1 (Ras converting enzyme 1) endoprotease catalyzes 
the cleavage of the –AAX peptide from the C-terminus. Finally, a methyl group is 
added to the prenylated cysteine by the Icmt (isoprenylcysteine-O-carboxyl 
methyltransferase) (99). The subcellular localizations of Rho GTPases are determined 
by their posttranslational modification. Cdc42 is widely distributed at the plasma 
membrane, Golgi, endoplasmic reticulum, and nuclear envelope, whereas Rac1 and 
RhoA predominantly associate with the plasma membrane (100).  
 The cellular functions of Rho GTPases largely depend on their subcellular 
localization. The lipid tails of GTPases insert into cellular membranes where they are 
able to engage their regulators: GEFs (Guanine nucleotide Exchange Factors), GAPs 
(GTPase-Activating Proteins), and GDIs (Guanine nucleotide Dissociation Inhibitors). 
GEFs promote the exchange of GDP for GTP, therefore activating Rho GTPases. 
GAPs markedly enhance the hydrolysis of GTP and thus inactivate GTPases. Rho 
GDIs sequester GDP-bound Rho GTPases in the cytosol by inhibiting nucleotide 
exchange (98, 101, 102). Rho GTPases switch between a GDP-bound inactive form 
and a GTP-bound active form to function as molecular switches to turn on and off 
signaling pathways.  
 
The Dbl Family GEFs 
Two families of GEFs have been identified for Rho GTPases: the classical Dbl 
family (103) and the recently discovered DOCK180 family (104-106). Dbl, as the 
founding member of Dbl family, was first identified as an oncogene in human diffuse 
B-cell lymphoma. Sequence analysis of Dbl uncovered a region with high homology 
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to the yeast Cdc24 protein which was shown to serve as a GEF for the yeast Cdc42 
protein (107). To date, about 70 members of the Dbl family have been identified, 
including the Rac1-specific GEF Tiam1 and the Cdc42-specific GEF Intersectin (101). 
All the Dbl family members contain two conserved domains, the Dbl homology (DH) 
and the pleckstrin homology (PH) domains. The DH domain is responsible for 
catalyzing nucleotide exchange, while the PH domain has been demonstrated to 
interact with the plasma membrane (108-111). 
Structural studies, especially the complex structure of Rac1 and DH-PH 
module of Tiam1, have elucidated the mechanism of how DH-PH domains of Dbl 
family members promote the nucleotide exchange of their cognate GTPases (96). The 
DH domain harbors three conserved regions (CR1-CR3) which form a three-helix 
bundle and provide the interface for Rac1 binding. The highly conserved residue 
Glu1047 from Tiam1 interacts via hydrogen bonding with three residues (Thr35, 
Val36, and Tyr32) from the switch I region of Rac1, which induces a conformational 
change within switch I, and subsequently destabilizes a bound Mg2+ ion and disrupts 
nucleotide binding. The Mg2+ ion binding site is further sterically blocked by the 
movement of Ala59 within the switch II region of Rac1, such that Ala59 forms a 
hydrogen bond with the highly conserved residue Lys1195 of Tiam1. Those structural 
features collectively delineate the mechanism of nucleotide exchange by Dbl family 
GEFs. 
The residues 1177-1179 in Tiam1, the most variant positions among other DH 
domains, contact residues from the β2- β3 strands of Rac1 thus accounting for the 
specificity of Tiam1 for Rac1 versus Cdc42 and RhoA. Biochemical studies have 
shown that position 56 of Rac1 or Cdc42 is pivotal for this specificity. Changing 
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Trp56 of Rac1 to Phe (the corresponding residue in Cdc42) prevented Rac1 from 
being activated by Tiam1, whereas the Rac1 (W56F) mutant could be activated by the 
Cdc42-specific GEF, Intersectin (112). Similarly, substitution of Phe at position 56 of 
Cdc42 for Trp enabled Cdc42 to be activated by Tiam1 but not by Intersectin. These 
studies demonstrated that position 56 of Rac1 and Cdc42 is necessary and sufficient 
for the specific recognition by their cognate Dbl family GEFs.  
In the Rac1-Tiam1 complex structure, the PH domain orientates away from the 
DH domain and fails to make contact with Rac1. Functionally, the DH domain 
exhibits full GEF activity in vitro. However, the PH domain is required for the 
transforming ability of Dbl in vivo (113). This suggests that the PH domain is 
necessary for the biological functions of Dbl family members. It has been proposed 
that the PH domain of Dbl family members is essential for membrane binding via 
interactions with phosphoinositides, albeit the binding of phosphoinositides to PH 
domains is weak and low in specificity (114, 115). Therefore, although the PH domain 
is essential for the cellular functions of Dbl proteins, the mechanism of how the PH 
domain regulates the GEF activity awaits further structural and biochemical 
investigation.  
 
The DOCK180 Family GEFs: Discovery, Functions, and Classification. 
The other family of GEFs for Rho GTPases is the atypical DOCK180 family, 
which shares no sequence similarity with the classical Dbl family of GEFs (116, 117). 
DOCK180-related proteins have been shown to activate Rac1 and/or Cdc42, but not 
RhoA. The founding member of the DOCK180 family, Ced-5, was originally 
identified as a binding partner for the oncogenic c-Crk protein in Caenorhabditis 
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elegans (105, 118). DOCK180 family proteins are evolutionarily conserved from 
worms, to flies and mammals. Eleven DOCK180-related proteins have been identified 
in mammals, designated as DOCK1-DOCK11 (DOCK1 is also known as DOCK180) 
(116, 119, 120) (Fig. 1.2).  
DOCK180 family members have been demonstrated to regulate multiple 
cellular processes, including cell migration and phagocytosis (118, 121-124), tumor 
suppression (125), and neuronal development and differentiation (126, 127). 
DOCK180 binds to the scaffold protein ELMO and forms a trimeric complex which 
activates Rac1. The Rac1 GTPase is a key regulator of the cell cytoskeleton and is 
essential for cell migration. Recently, RhoG, activated by the GEF TRIO, was found 
to be functioning upstream of the CrkII/ELMO/DOCK180/Rac1 pathway, which is 
essential for the engulfment of apoptotic cells (124). DOCK4, indentified as a Rap1 
GEF, has been shown to be mutated in some human cancer cells, including prostate 
and ovarian cancers. Overexpression of wild type DOCK4 in mouse osteosarcoma 
cells represses cell growth and tumor invasion (125). DOCK180-related proteins play 
important roles in almost every process of neuronal cell development, including 
migration, neurite outgrowth, axon guidance, and synapse formation. DOCK1 and 
DOCK3 have been reported to promote neurite outgrowth induced by the signaling of 
nerve growth factor (NGF) in PC12 cells (126). DOCK7 has been demonstrated to be 
activated by the growth factor neuregulin-1 (NRG-1) and to regulate axon formation 
through Rac1 and Cdc42 activation (127). DOCK4 and DOCK9 have been shown to 
be enriched in hyppocampal neurons and to be associated with the synapse formation. 
The eleven mammalian DOCK proteins are classified into four subfamilies: 
DOCK-A to DOCK-D subfamily (117) (Fig. 1.2). The DOCK-A subfamily contains 
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DOCK1, 2, and 5, while the DOCK-B subfamily consists of DOCK3 and DOCK4. 
Proteins within these two subfamilies share 50-65% sequence identity. Only members 
in the subfamilies DOCK-A and DOCK-B possess the proline-rich motif PxxP which 
mediates the interaction with c-CRK protein. Also, DOCK-A and DOCK-B members 
have a SH3 domain in the N-terminus. This SH3 domain can interact with the PxxP 
motif within the C-terminus of the same DOCK protein and mediate autoinhibition of 
the GEF activity. The binding with other regulatory proteins can release the 
autoinhibhition by binding to the SH3 domain and enhance the accessibility of the 
DHR2 domain to its cognate GTPase. DOCK6-8 fall within the DOCK-C subfamily, 
and DOCK9-11 comprise the DOCK-D subfamily. The DOCK-C subfamily is more 
related to the DOCK-D subfamily than to the DOCK-A/B subfamily, with about 30% 
sequence identity with DOCK-D members. The DOCK-D proteins contain an N-
terminal PH domain which has been proposed to be important for membrane targeting 
and protein-protein interactions (128). 
 
Regulation of DOCK180 Family Proteins 
To date, little work has been done to study the regulation of DOCK180-related 
proteins. Recently, a few studies have been conducted on some DOCK180 members, 
including DOCK180 and DOCK7. Given the primary sequence similarity of the 
members within the family, it is likely that the regulatory mechanism found for a 
specific member might be shared with the whole family, although further research is 
required to confirm this idea.  
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Figure 1.2. The eleven members of the DOCK180 family in mammals (adapted from 
reference 128). DOCK180 family was classified into DOCK-A, B, C, D subfamilies. 
One of the significant characteristics of DOCK180 family is that all the members 
harbor two DOCK homology domains: DHR1 and DHR2. Two residues: Met and Asn 
in DOCK-A subfamily, Leu and Gln in DOCK-D subfamily, are important for the 
specific recognition of Rac and Cdc42, respectively. The corresponding residues in 
DOCK-C subfamily are Met and Gln.  
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• Associating with Phosphoinositides 
The DHR1 domain of DOCK180 has been shown to interact with PtdIns 
(3,4,5) P3 (PIP3), which enhances the translocation of DOCK180 from the cytosol to 
the plasma membrane (129). This occurs in response to PIP3 produced by the 
phosphatidyinositol 3-kinase (PI3K) upon the stimulation of growth factors. The 
DHR1 domain is highly conserved among members of the DOCK180 family. Thus, 
the mechanism of associating with phosphoinositides can be applied by other members 
to translocate to the membrane and to activate downstream targets.  
• Binding to Adaptors 
DOCK180 was originally found to bind to the SH3 domain of CrkII, an 
adaptor protein which also contains an SH2 domain for binding to phosphorylated 
tyrosine residues (105). Additionally, the DOCK180-CrkII complex is always found 
bound to ELMO proteins via the interaction between the SH3 motif of DOCK180 and 
the PxxP motif of ELMO (116). ELMO1 is essential for the full GEF activity of 
DOCK180 and for the subsequent activation of Rac1 by DOCK180. All the DOCK-A 
and DOCK-B subfamily members possess an SH3 motif within their N-terminus. 
Therefore, interacting with adaptors can be a common approach utilized by 
DOCK180-related proteins to regulate their cellular functions. 
• Inter- and Intra- Molecular Interactions 
It has been reported that the N-terminus of DOCK9 DHR2 domain mediates 
the dimerization of the protein, which enhances its GEF activity (120). Additionally, 
the N-terminal SH3 domain of DOCK180 binds to the C-terminal PxxP motif, leading 
to the subsequent autoinhibition of its GEF activity (130). This autoinhibition 
mechanism can be applied to other DOCK-A and DOCK-B subfamily members, 
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because they all harbor these SH3 and PxxP motives. DOCK11 has been found to 
interact with the active form of Cdc42, and this binding of active Cdc42 further 
activates DOCK11, forming a positive feedback activation loop (131).  
• Phosphorylation 
The activities of the classical Dbl family GEFs are modulated by 
serine/threonine phosphorylation (132, 133). Similarly, DOCK180 was found be 
phosphorylated on serine/threonine residues (134). Interestingly, DOCK7 has been 
demonstrated to be directly phosphorylated on residue Tyr1118 by the EGF receptor 
family member ErbB2, in a heregulin-dependent manner (127). This tyrosine 
phosphorylation directly activates DOCK7 to promote the nucleotide exchange of the 
downstream GTPases Rac1 and Cdc42. DOCK7 belongs to the DOCK-C subfamily 
which is different from the other three subfamilies that have either SH3, PxxP, or PH 
motifs for intermolecular interactions. Herein, it is possible that DOCK-C subfamily 
members may act as direct substrates of signaling molecules that regulate their GEF 
activity.  
• Ubiquitination   
DOCK180 was more stable when overexpressed with ELMO in cells, which 
suggested that ELMO might block the ubiquitination and subsequent degradation of 
DOCK180 (135). However, the ubiquitinaiton of DOCK180 has still not been 
definitively demonstrated. 
 
The DHR1 and DHR2 Domains of DOCK180 Family 
One of the major features of the DOCK180 family is that all members possess 
two DOCK homology regions, DHR1 and DHR2, which do not share sequence 
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similarity with PH and DH domains of the Dbl family (117). The DHR1 domain is 
located in the N-terminus of DOCK180 family members and consists of about 250 
residues, which share weak homology with the C2 domains found in the DOCK-A and 
DOCK-B subfamilies, whereas no C2 homology was found in the DHR1 domain of 
the DOCK-C or DOCK-D subfamily members. The DHR1 domain of DOCK1 has 
been demonstrated to specifically bind to PIP3-enriched membranes (129). The X-ray 
crystal structure of the DHR1 domain of DOCK1 has revealed that several highly 
conserved residues (such as lysine and arginine residues) present on the surface form a 
highly basic pocket to accommodate the negatively charged PIP3 from cellular 
membranes (136). The GEF activity of DOCK1 is independent from the DHR1 
domain. However, DHR1 has an important functional role as it has been shown to be 
required for Rac1-mediated cell polarity and cell elongation. 
The DHR2 domain is located downstream of the DHR1 domain and consists of 
about 500 residues which are highly conserved among the DOCK180 family. The 
DHR2 domain shares no sequence similarity with the DH domain from the Dbl family 
GEFs. Therefore, the DOCK180 family members are referred to as the atypical Rho 
GEFs. Previously, the DHR2 domain has been demonstrated to be necessary and 
sufficient to activate GTPases. However, a recent study on DOCK180 showed that a 
limited C-terminal portion of the DHR2 domain of DOCK180 displayed full GEF 
activity (137). The N-terminus of the DOCK9 DHR2 domain is responsible for 
dimerization which may play a role in promoting its maximal GEF activity (120, 138). 
This suggested that all the DOCK proteins might exist as homodimers, with 
dimerization being mediated by the N-terminal portion of the DHR2 domain.  
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The Specificity of DOCK180 Family on Rac and/or Cdc42 
A good deal of biochemical studies have established that the DOCK-A and 
DOCK-B subfamily members are Rac-specific GEFs, while the DOCK-D proteins can 
only specifically activate Cdc42 (117, 139). It is proposed that the DOCK-C subfamily 
exhibits no specificity and can recognize both Rac1 and Cdc42 (127, 140). What is the 
mechanism by which DOCK180 GEFs activate Rho GTPases? Why do different 
subfamilies recognize different Rho G-proteins? Structural studies on the DOCK9-
Cdc42 and DOCK2-Rac1 complexes have elucidated the activation mechanism and 
shed light on how the specificity of the DOCK180 proteins toward their substrate 
GTPases is manifested (138). The overall structure of the DOCK9-DHR2 domain 
consists of three lobes: lobe A-C, of which lobe A comes from the N-terminal portion 
of DHR2 and provides critical intermolecular interactions for dimerization. Lobe B 
and C make contacts with the switch I and switch II domains of Cdc42 and cause 
conformational changes only in switch I, which is different from Dbl GEFs that cause 
conformational changes in both switch I and switch II. Upon the binding of DHR2, the 
residue Phe28 of Cdc42 inserts into the hydrophobic pocket of lobe B and weakens the 
binding of GDP. The nucleotide sensor of DHR2, the α10 insert, moves to the 
nucleotide-binding site of Cdc42. Within this α10 insert sensor, an invariant residue 
from plants to humans, Val1951, helps to exclude Mg2+, therefore further destabilizing 
GDP binding. For Dbl GEFs, the binding of the GEF also induces a conformational 
change in switch II, which moves a highly conserved Ala residue into the position 
normally occupied by Mg2+, thereby releasing Mg2+ from the GTPase. The invariant 
Val residue suggests that all of the DOCK180 proteins share the same mechanism for 
activating their cognate GTPases. This is further supported by the observation that the 
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replacement of valine with alanine abolished the GEF activity of DOCK9 and 
DOCK1. 
Biochemical studies have shown that several residues in the switch I and β2-β3 
regions of Rac or Cdc42 are important for the specific recognition by their cognate 
DOCK proteins (137, 139). These residues include Ala27, Gly30, and Trp56 for Rac, 
and Lys27, Ser30, and Phe56 for Cdc42, through which Rac and Cdc42 undergo 
interactions with DOCK proteins. Rac-to-Cdc42 substitutions of these residues can 
enable Rac to at least be partially activated by the Cdc42-specific DOCK9 DHR2, and 
vice versa. Among those residues, position 56 is the key residue for specific 
recognition, given that the Rac1 W56F mutant only showed basal activation by the 
DOCK1 DRH2c. In the X-ray crystal structure of the DOCK9-Cdc42 complex (or the 
DOCK2-Rac complex) (138, 141), the side chain of Phe56 (or Trp56) interacts with 
Leu1941 and Gln1944 (or Met1529 and Asn1532) of the DOCK9 (or the DOCK2) 
DHR2 domain. Replacing Met1524 of the DOCK1 DHR2c with leucine eliminated 
about 75% of the activation of wild-type Rac1, while restoring about 50% of the 
activation of the Rac1 W56F mutant. This suggests that Met1524 is crucial for the 
ability of DOCK1 to distinguish Rac1 from Cdc42. It is reasonable to assume that 
residue Asn1527 in DOCK1 (Asn1532 in DOCK2 and compartment Gln1944 in 
DOCK9) should also be important for the specific recognition of Rac1 (Rac2 and 
Cdc42). 
However, little is known regarding why DOCK-C subfamily members 
(including DOCK6-8) are capable of the dual recognition of Rac and Cdc42, given 
that DOCK-C members have not exhibited robust GEF activity yet in vitro. It is 
controversial that DOCK7 can activate both Cdc42 and Rac1, due to the conflicting 
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results from in vitro GEF assays (127, 142). Similarly, one study reported that 
DOCK6 showed no catalytic activity toward either Rac or Cdc42 (140). Therefore, it 
will be interesting to ultimately characterize the DOCK-C subfamily members. 
 
 In chapter 5, I show that the DOCK7-DHR2 domain is a potent GEF for 
prenylated Cdc42 and Rac1 in a model liposome system, demonstrating that the 
prenylation and resulting membrane localization of Cdc42 or Rac1 are pivotal for the 
activation by DOCK7. Additionally, as demonstrated previously for DOCK1 (137), 
we show that DOCK7 harbors residues that impart GEF specificity and these can be 
mutated to shift a given DOCK-DHR2 activity profile. Finally, using our liposome 
reconstitution assays, we show that the DOCK7-DHR2 limit domain (DHR2s) 
possesses an N-terminal site distinct from the nucleotide exchange active site that 
binds preferentially to the active forms of Cdc42 and Rac1, which helps to recruit 
DOCK7 to the membrane. This recruitment results in an increase in the effective 
concentration of the GEF at the membrane surface that in turn provides for an 
accelerated rate of nucleotide exchange for prenylated Cdc42 in the presence of 
liposomes.  
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Chapter 2 
SIRT5 is an NAD-dependent Demalonylase and Desuccinylase1 
2.1 Introduction 
Silent Information Regulator 2 (Sir2) proteins, or sirtuins, are a class of evolutionally 
conserved enzymes with nicotinamide adenine dinucleotide (NAD)-dependent protein 
deacetylation activity (Fig. 2.1) and putative ADP-ribosyltransferase activity (1, 2). 
Since the initial discovery of the deacetylase activity of sirtuins by Guarente and 
coworkers (3), many important biological functions of sirtuins have been revealed (2), 
including the regulation of life span (3-8), transcription (9-11), apoptosis and cell 
survival (12-16), genome stability (17, 18) and metabolism (8,19-25). The NAD-
dependent deacetylation mechanism of sirtuins has been studied extensively and the 
generally accepted mechanism is shown in Fig. 1.1 (26-30). Several crystal structures 
of sirtuins have been reported which support the proposed enzymatic reaction 
mechanism (31-33). 
There are seven sirtuins in mammals, SIRT1-7. Three of them, SIRT3, SIRT4, 
and SIRT5, are in mitochondria and possibly regulate metabolic pathways in 
mitochondria (34). All other sirtuins are either nuclear or cytosolic. Based on sequence 
similarity, sirtuins from different species can be grouped into different classes (35). 
Mammalian SIRT1, SIRT2, and SIRT3 belong to Class I, SIRT4 belongs to Class II, 
SIRT5 belongs to Class III, and SIRT6 and SIRT7 belong to Class IV. Of the seven  
                                                 
1  This work was published in Science 334, 806-809. AAAS’ License to Publish allows me to 
include this paper in my dissertation. I was a co-first author, responsible for the protein 
purification, crystallization, X-ray diffraction data collection, and structure determination of 
all the SIRT5 complexes. Some of the figures have been rearranged for readers’ convenience.   
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Figure 2.1. The sirtuins catalyzed NAD-dependent deacylation reaction. The reaction 
generates O-acyl-ADP-ribose. 
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mammalian sirtuins, only Class I sirtuins (SIRT1, SIRT2, and SIRT3) have been 
shown to have robust deacetylase activity. SIRT4 has no detectable deacetylase 
activity (23, 34). SIRT5 was reported to have weak deacetylase activity (36) and our 
own work (see below) further confirmed this. SIRT6 was originally reported to lack 
deacetylase activity (34, 37), but a recent report from Chua and coworkers suggested 
that SIRT6 can specifically deacetylate Histone H3 K9 (18). However, the in vitro 
activity is weak (18). No activity has been detected for SIRT7 (34), which localizes in 
the nucleolus.  
What is the biochemical function of sirtuins with little or no deacetylation 
activity (i.e. Class II, III and IV sirtuins)? It has been suggested that sirtuins lacking 
deacetylase activity could function as protein ADP-ribosyltransferases (23, 37). We 
and others have studied the ADP-ribosylation activity of sirtuins and found that it is 
orders of magnitude slower than the deacetylase activity of Class I sirtuins or the 
ADP-ribosylation activity of a bacterial ADP-ribosyltransferase, diphtheria toxin (38, 
39). Here we present data showing that mammalian SIRT5 is an NAD-dependent 
demalonylase and desuccinylase in vitro (Fig. 2.1) with catalytic efficiencies similar to 
that of SIRT1-catalyzed deacetylation. Furthermore, we show that protein 
succinylation and malonylation exist in mammalian proteins. The finding that SIRT5 
prefers to hydrolyze succinyl/malonyl lysine residues suggests that other sirtuins that 
show little or no deacetylase activity may also prefer acyl groups other than acetyl. 
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2.2 Experimental Procedures 
Cloning, Expression and Purification of Human Sirtuins. Human SIRT1-3, 5, and 6 
were expressed as previously described (39). Human SIRT7 coding sequence was 
PCR-amplified using primers JT072_SIRT7 (1-400) EcoRI5 (5’-AGTCAGGAA 
TTCATGGCAGCCGGGGGTCT-3’) and JT073_SIRT7 (1-400) XhoI3 (5’-
AGTCAGCTCGAGT TACGTCACTTTCTTCCTTTTT-3’). Amplified product was 
digested with EcoRI and XhoI. The digested PCR product was purified and ligated 
into the similarly digested expression vector pET28a. C-terminal Flag-tagged SIRT5 
(Flag-SIRT5) and truncated SIRT5(34-302) were cloned using TOPO and Gateway 
cloning technology (Invitrogen Corp., Carlsbad, CA) into pDEST-F1 for expression. 
SIRT7, Flag-SIRT5 and SIRT5(34-302) were expressed in E. coli and purified as 
described (39). After purification, Flag-SIRT5 and SIRT5(34-302) were digested by 
TEV at room temperature for 2 h and purified by HisTrapTM HP Column (GE 
Healthcare, Piscataway, NJ) and gel filtration on a HiLoad 26/60 Superdex 75 prep 
grade column (GE Healthcare, Piscataway, NJ). Protein was dialyzed into 
crystallization buffer (20 mM Tris, pH 8.0, 20 mM NaCl, 5% glycerol), concentrated 
into 16 mg/mL, flash frozen by liquid nitrogen, and stored at -80 °C for crystallization.  
Protein Crystallization. P53K382 acetyl, or thioacetyl peptide, Histone H3K9 acetyl, 
or thioacetyl, or malonyl, or succinyl, or thiosuccinyl peptide [4- KQTAR (ac, tac, 
mal, suc) STGGKA-15] was used for crystallization. 50 mM peptide stock solutions 
were made by dissolving peptide powder in double distilled water and neutralized with 
8 M NaOH before mixed with SIRT5. SIRT5-peptide mixtures were prepared at a 
1:20 protein:peptide molar ratio and incubated for 30~60 min on ice. The final protein 
concentration was 10 mg/mL. Crystals were grown by the method of hanging drop 
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vapor diffusion. H3K9 acetyl and malonyl peptide failed to give any crystals under the 
conditions I’ve tried. The SIRT5-H3K9 thioacetyl peptide cocrystals were grown in 
the condition of 20% PEG8000, 0.1 M CHES, pH 9.5 at 18 °C. The SIRT5-H3K9 
succinyl peptide co-crystals were grown in the condition of 16% PEG4K, 6% Glycerol 
at 18 °C, while the SIRT5-H3K9 thiosuccinyl peptide co-crystals were grown in the 
condition of 30% PEG10k, 0.1 M TRIS, pH8.5 at room temperature.  
Data Collection and Structure Determination. 15% Glycerol was added to the mother 
liquid as the cryoprotectant for SIRT5-H3K9 thioacetyl co-crystals. SIRT5-H3K9 
succinyl co-crystals were soaked in the cryoprotectant solution (18% PEG4K, 15% 
Glycerol) with 10 mM NAD for 2-10 minutes at room temperature immediately before 
data collection. To obtain the intermediate structure, SIRT5-H3K9 thiosuccinyl co-
crystals were soaked in the cryoprotectant solution (30% PEG10k, 0.1 M TRIS, 
pH8.5, 15% Glycerol) with 10 mM NAD for 2-5 hours at 4 °C, and flash frozen in 
liquid nitrogen for data collection. All the X-ray diffraction data were collected at 
CHESS (Cornell High Energy Synchrotron Source) A1 or F1 station. The data were 
processed using the programs HKL2000 (40). All the structures of SIRT5 complexes 
were solved by molecular replacement using the program Molrep from the CCP4 suite 
of programs (41). The SIRT5-ADPR structure (PDB code: 2B4Y) was served as the 
search model. Refinement and model building were performed with REFMAC5 and 
COOT from CCP4. The X-ray diffraction data collection and structure refinement 
statistics are shown in Table 2.1. 
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Table 2.1. Crystallographic data collection and refinement statistics. 
 SIRT5-Thioacetyl H3K9 SIRT5-Succinyl H3K9-NAD 
Data collection   
Space group P212121 P212121 
Cell dimensions   
         a, b, c (Å) 52.54, 67.88, 156.75 52.69, 69.41, 156.32 
         α, β, γ (º) 90, 90, 90 90, 90, 90 
Resolution (Å) 50-2.00 50-1.55 
Rsym or Rmerge (%) 9.0 (34.4) 6.6 (39.8) 
I /σI 38.65 (4.23) 42.26 (5.15) 
Completeness (%) 99.9 (99.8) 99.7 (98.5) 
Redundancy 6.8 (5.3) 7.1 (5.7) 
   
Refinement   
Resolution (Å) 30-2.00 30-1.55 
No. reflections 39228 79514 
Rwork / Rfree (%) 21.52/25.80 14.26/19.09 
No. of protein atoms 8170 8170 
No. of ligand/ion molecules   
          Thioacetyl H3K9 2 --- 
          Succinyl H3K9 --- 2 
          CHES 2 --- 
          NAD --- 2 
          Zn 2 2 
No. of water 187 732 
R.m.s deviations   
          Bond lengths (Å) 0.0256 0.0230 
          Bond angles (º) 1.774 2.031 
Numbers showed in the parentheses are for the highest resolution shell. 
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Deacetylation, Demalonylation, and Desuccinylation Activity Assay and 
Determination of kcat and Km. The deacylase activity of human SIRT1, SIRT2, SIRT3, 
SIRT5, SIRT6 and SIRT7 were measured by detecting the deacylated peptide from the 
acyl peptides using LC-MS. Purified sirtuin was incubated with 0.3 mM acyl peptides, 
1.0 mM NAD in 20 mM Tris-HCl buffer (pH 7.5) containing 1 mM DTT in 60 μL 
reactions for 2 h at 37°C. The reactions were stopped with 60 μL 10% TFA and 
analyzed by LC-MS. 
For determination of kcat and Km, human SIRT1, SIRT2, SIRT3 and SIRT5 were 
measured by detecting the deacylated peptide from H3K9 acyl peptides using HPLC. 
Purified sirtuin was incubated with 1.0 mM of NAD in 20 mM Tris-HCl buffer (pH 
7.5) containing acyl peptides (0–750 μM) and 1 mM DTT in 60 μL reactions at 37°C. 
The reactions were stopped with 100 mM HCl and 160 mM acetic acid, analyzed by 
HPLC with a reverse phase C18 column (250 × 4.6 mm, 90 A, 10 μm, GraceVydac, 
Southborough, MA), with a linear gradient of 0% to 20% B for 10 min (1 mL/min). 
Product quantification was based on the area of absorption monitored at 215 nm, 
assuming hydrolysis of the acyl group does not affect the absorption. The kcat and Km 
values were obtained by curve-fitting the Vinitial/[E] versus [S] plot using 
KaleidaGraph. For SIRT5 R105M, the observed second order rate constant, kobs 
(rate/([sirtuin][NAD])) was detected instead of kcat and Km because of the very weak 
deacylation activity. The experiments were done in duplicate.    
For comparing the deacetylation, demalonylation and desuccinylation activities 
of SIRT5 on different peptide backbones, histone H3, GDH and ACS2 peptides with 
two tryptophan residues at the C-terminal were used to allow better detection and 
quantification on HPLC. The determination of kcat and Km was carried out essentially 
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the same as mentioned above with slight modifications. The reactions were quenched 
with 60 μL 10% TFA. The chromatography gradient was 0% to 50% B for 20 min (1 
mL/min). The peptides were detected and quantified on the LC by the absorption at 
280 nm. 
Purification of O-Ma-ADPR and O-Su-ADPR with HPLC and Analysis by MS. SIRT5 
or SIRT1 (1 μM) was incubated with 0.5 mM malonyl or succinyl peptides and 1.0 
mM NAD in 20 mM Tris-HCl buffer (pH 7.5) with 1 mM DTT in 60 L reactions for 2 
h at 37°C. The reactions were terminated by adding 60 μL 10% TFA. After 
centrifugation to remove precipitated proteins, the supernatant was analyzed by HPLC 
using a 50 mM ammonium acetate isocratic system on a Sprite TARGA C18 column 
(40 × 2.1 mm, 5 μm, Higgins Analytical, Inc.). The product O-Ma-ADPR (retention 
time 1.6 min) and O-Su-ADPR (retention time 2.3 min) was collected and the 
molecular weights were confirmed by MALDI-MS. The ADPR (retention time 1.2 
min) and NAD (retention time 5 min) have also been confirmed by MALDI-MS. 
O-Su-ADPR generated from bovine liver mitochondrial peptide mixtures was 
purified as above and analyzed using an Agilent 1100 high-performance liquid 
chromatographer coupled to an ABI 4000 Q-trap mass spectrometer operating in IDA 
negative ion mode. Chromatography consisted of an HILIC column (Nest Group, 
100 Å, 5 μm, polyhydroxyethyl A, 1 × 150 mm) eluted with a gradient of acetonitrile 
versus 10 mM ammonium acetate at 0.05 ml/min. This extra LC step was needed 
because the sample was more complicated than the reactions using only synthetic 
peptides. 
Detection of Succinyl Lysine from Bovine Liver Mitochondrial Proteins Using the 32P-
NAD Assay. Bovine liver mitochondria was isolated as previously described (42). 
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Mitochondria from 5 g bovine liver was lysed for 30 min at 4°C in ice-cold lysis 
buffer (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 0.1% Triton X-100) containing 
protease cocktail inhibitor (P8340, Sigma). The supernatants were collected and 
exchanged to 25 mM Tris-HCl (pH 8.0) with 50 mM NaCl using centrifugal filter 
(MILLIPORE, Billerica, MA) to remove endogenous NAD. The extracts were stored 
at -80°C.  For trypsin digestion, 1.5 mg of the bovine liver mitochondria proteins or 
BSA (used as the control) was dissolved in 6 M urea, 60 mM Tris-HCl (pH 8.0), 15 
mM DTT in a reaction volume of 450 μL. The solution was heated at 95°C for 15 min 
and then cooled to room temperature. Then 22.5 μL of 1M iodoacetamide (final 
concentration ~50 mM) was added and the mixture was incubated at room temperature 
with gentle mixing for 1 h. Then 3.6 mL of 50 mM Tris-HCl (pH 7.4) with 1 mM 
CaCl2 was added to the reaction mixture to lower the urea concentration to 0.75 M.  
Finally, 150 μL of 100 μg/mL modified trypsin (Promega Corporation, Madison, WI) 
were added and the reaction mixture was incubated at 37 °C for 12 h. After quenching 
the reaction by adding 65 μL 10% TFA to pH 2~3, the digested peptides were desalted 
by using Sep-Pak C18 cartridge 1cc/50 mg (Waters Corporation, Milford, MA) and 
lyophilized.  
To detect the acyl-ADPR compounds formed in sirtuin-catalyzed deacylation 
reactions, reactions were performed in 10 μL solutions with 1 μCi 32P-NAD (ARC 
Inc., ARP 0141, 800Ci/mmol, 0.125μM), 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 
mM DTT. The acyl peptide substrates used were 100 μM H3K9 acetyl, malonyl, or 
succinyl peptide, 2 μg calf thymus histones (Roche Applied Science, Indianapolis, 
IN), 20 μg bovine liver mitochondrial peptides, or 20 μg BSA peptides. The reactions 
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were incubated with 1 μM SIRT5 or SIRT1 at 37°C for 1 h. CD38 catalytic domain 
was used to generate ADPR as a control. A total of 0.5 μL of each reaction were 
spotted onto silica gel TLC plates and developed with 7:3 ethanol:ammonium 
bicarbonate (1 M aqueous solution). After development, the plates were air-dried and 
exposed to a PhosphorImaging screen (GE Healthcare, Piscataway, NJ). The signal 
was detected using a STORM860 phosphorimager (GE Healthcare, Piscataway, NJ). 
Affinity Purification of Lysine-succinyl Peptides and Protein Identification. Flag-
SIRT5 (25 μg) was bound onto 100 μL anti-Flag M2 affinity gel (A2220, Sigma) by 
incubation at 4°C in NETN buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM 
EDTA, 0.5% NP40) for 2 hr (43). The supernatant was removed and the gel was 
washed three times with NETN buffer. The tryptic mitochondria peptides (~1 mg) 
obtained above were resolubilized in 0.5 mL NETN buffer and insoluble particles 
were removed by centrifugation at 10,000 × g for 10 min. Affinity purification was 
carried out by incubating the peptides with Flag-SIRT5 bound anti-Flag M2 affinity 
gel at 4°C for 3 h with gentle shaking. The gel was washed three times with 1 mL of 
NETN buffer and twice with ETN buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 
mM EDTA). The bound peptides were eluted three times with 100 μL of 0.1% TFA. 
The elutions were combined and lyophilized. The resulting peptides were cleaned 
using C18 ZipTips (Millipore, Bedford, Massachusetts) according to the 
manufacture’s instructions, prior to LC-MS/MS analysis performed at the Proteomic 
and MS Facility of Cornell University. Tandem mass spectra were searched against 
NCBI-nr database with MASCOT search engine (Matrix Science, London, UK) using 
acetyl, malonyl, and succinyl lysine as modifications. 
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Detection of Lysine Succinylation on CPS1 Peptides Using the 32P-NAD Assay. The 
CPS1 band was cut from a SDS-PAGE gel of the bovine liver mitochondria lysate. 
The protein was in-gel digested with trypsin and extracted and desalted as the 
following. The gel band was washed in 100 μL water for 5 min, followed by 100 μL 
100 mM Ammonium bicarbonate : acetonitrile (1:1) for 10 min and finally 50 μL 
acetonitrile for 5 min. The acetonitrile was then discarded and the gel band was 
allowed to dry in the ventilated fume hood for 5-10 min. The gel slice was then 
rehydrated with 15 μL trypsin solution (10 μg/mL modified trypsin in 1mM HCl) on 
ice for 30 min. The trypsin solution was topped with 10 μL 50 mM Ammonium 
bicarbonate with 10% acetonitrile. The digestion reactions were kept at 30°C for 12 h.  
The resulting solution was acidified with formic acid (1% in final). The trypsin 
digested peptides were extracted twice with 30 μl of 50% acetonitrile with 0.2% TFA 
(45 min incubation at room temperature followed by 5 min sonication). The third 
extraction was done with 30 μl of 90% acetonitrile with 0.2% TFA (5 min). All the 
extracts were combined and lyophilized. When dried, the peptides were dissolved in 
12 μl of 0.1% TFA and desalted by ZipTips (Millipore, Bedford, Massachusetts).  
The desalted peptides were lyophilized again and reconstituted in water. The GDH 
peptides from in-gel digestion and the histone peptides from in-solution digestion were 
prepared as described above. The 32P-NAD assays were carried out as described above.  
To lower the detection limit, higher concentrations of sirtuins were used. The SIRT5 
was used at a final concentration of 52 μM and the Hst2 was used at 24 μM. The 
sample peptides were used at a concentration of 0.3 μg/μl and the control peptides 
were at 20 μM. 
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Generation of SIRT5 Deficient Mouse Line. SIRT5 +/+ and -/- mice were generated at 
the Institut Clinique de la Souris (Strasbourg, France). Briefly, exon 4 of SIRT5 locus 
was flanked with loxP sites using standard genetic engineering and gene targeting 
procedures. The resulting SIRT5 floxed mice were bred with CMV-Cre transgenic 
mice to generate germline SIRT5 deficient (SIRT5 -/-) mice and control SIRT5 +/+ 
mice. The absence of SIRT5 mRNA in different tissues of SIRT5 -/- mice was 
confirmed by Q-RT-PCR analysis and the loss of SIRT5 protein expression was 
verified by western blot using an anti-SIRT5 antibody (Abcam ab62740). 
Detection of Succinylation Level on CPS1 from SIRT5 wt and KO Mouse Livers Using 
the 32P-NAD Assay. The 29-week-old male SIRT5 +/+ and -/- littermates were fasted 
overnight (from 6:00 PM to 10:00 AM) and then provided with free access to food for 
four hours prior to sacrifice. Liver tissues were rapidly removed, snap-frozen with 
liquid nitrogen, and stored at -80°C for analysis. The liver samples were first broken 
into small pieces, and then homogenized in 1mL of the lysis buffer (50 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% NP-40, 10% glycerol). The crude lysates 
were incubated at 4°C on shaker for 30 min then centrifuged at 10 000 g, 4°C for 10 
min. The concentration of the lysate was determined by Bradford assay.   
The lysate with total protein of 200 μg was incubated with 3 μl of the CPS1 
antibody (Abcam ab3682) at 4°C for 60min. 40 μl of the Protein A/G agarose beads 
(Santa Cruz Biotechnology sc-2003) was then added and incubated at 4°C overnight. 
The beads were washed 3 times in Tris buffer (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 
0.1% NP-40). The beads with the immunopurified CPS1 (0.5-1.0 μg) was incubated 
with 1 μCi 32P-NAD and 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM DTT. The 
SIRT5 was used at the concentration of 10 μM and Hst2 was used at 1 μM. The 
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control peptides were used all at 20 μM concentration. The reaction was incubated at 
37°C for 1 h. 1.8 μL sample was loaded onto the TLC plate. Separation by TLC and 
detection by autoradiography was performed as described above. 
Identification of Acyl Lysine Residues from Commercial Proteins by LC-MS/MS. 
Commercial GDH (Sigma G2626), malate dehydrogenase (Sigma M2634), citrate 
synthase (Sigma C3260), and pyruvate dehydrogenase (Sigma P7032) were in-
solution digested with trypsin. Typically, 1.0 mg of the protein was dissolved in 6 M 
guanidine hydrochloride, 150 mM Tris-HCl (pH 8.0), 15 mM DTT in a reaction 
volume of 400 μL. The solution was incubated at room temperature for 60 min. Then 
20 μL of 1M iodoacetamide (final concentration ~50 mM) was added and the mixture 
was incubated at room temperature with gentle mixing for another 60 min. The excess 
iodoacetamide was quenched with 40mM DTT. Then 3.6 mL of 50 mM Tris-HCl (pH 
7.4) with 1 mM CaCl2 was added to the reaction mixture to lower the guanidine 
hydrochloride concentration to 0.6 M. Finally, 100 μL of 100 μg/mL modified trypsin 
(Promega Corporation, Madison, WI) were added and the reaction mixture was 
incubated at 37 °C for 12 h. After quenching the reaction by adding 65 μL 10% TFA 
to pH 2~3, the digested peptides were desalted by using Sep-Pak C18 cartridge 1cc/50 
mg (Waters Corporation, Milford, MA) and lyophilized.  
Identification of Protein Acylation by nanoLC/MS/MS Analyses. The tryptic digest was 
reconstituted in 50 μL of 2% acetonitrile with 0.5% formic acid. About 200 ng of 
tryptic digest were injected for nanoLC-ESI-MS/MS analysis. The initial analysis was 
performed in UltiMatePlus nanoLC (Dionex, Sunnyvale, CA) coupled with to a hybrid 
triple quadrupole linear ion trap mass spectrometer, 4000 Q Trap from ABI/MDS 
Sciex (Framingham, MA) equipped with Micro Ion Spray Head II ion source. 
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Additional analysis was carried out using UltiMate3000 nanoLC (Dionex, Sunnyvale, 
CA) coupled with a LTQ Orbitrap Velos (Thermo-Fisher Scientific, San Jose, CA) 
mass spectrometer equipped with “Plug and Play” nano ion source device 
(CorSolutions LLC, Ithaca, NY). 
Tryptic peptides were separated on a PepMap C-18 RP nano column (5 µm, 75 
µm i.d. × 150 mm, Dionex), eluted in a 60 to 90-minute gradient of 10% to 40% 
acetonitrile in 0.1% formic acid at 300 nL/min. For 4000 Q Trap analysis, MS data 
acquisition was acquired using Analyst 1.4.2 software (AB SCIEX, Framingham, MA) 
in the positive ion mode for information dependant acquisition (IDA) analysis with 
nanospray voltage at 1.85 kV and heated interface at 150°C used for all experiments. 
In IDA analysis, after each survey and an enhanced resolution scan, three highest 
intensity ions with multiple charge states were selected for tandem MS (MS/MS) with 
rolling collision energy applied for detected ions based on different charge states and 
m/z values. For Orbitrap analysis, each of tryptic digests was acquired at both CID-
based parallel data-dependent acquisition (DDA) mode where FT mass analyzer was 
used for one survey MS scan followed by MS/MS scans on top 7 most intensity peaks 
with multiple charged ions above a threshold ion count of 5000 in LTQ mass analyzer, 
and HCD-based DDA mode where one FT survey scan was followed by 5 MS/MS 
scan in FT analyzer. MS survey scans and MS/MS scans were acquired at a resolution 
of 60,000 and 7,500 (fwhm at m/z 400) respectively. The Orbitrap Velos is operated in 
positive ion mode with nano spray voltage set at 1.5 kV and source temperature at 225 
°C. Either internal calibration using the background ion signal at m/z 445.120025 as a 
lock mass or external calibration using Ultramark 1621 for FT mass analyzer is 
performed. The normalized collision energy for CID and HCD were set at 35 % and 
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38% respectively. All data are acquired under Xcalibur 2.1 operation software 
(Thermo-Fisher Scientific).  
The MS/MS data generated from both 4000 Q Trap and LTQ Orbitrap Velos 
were submitted to Mascot 2.3 (Matrix Science, Boston, MA) for database searching 
using in-house licensed Mascot local server and the search was performed to query to 
SwissProt database (taxonomy: mammal) with three missed cleavage sites by trypsin 
allowed. The peptide tolerance was set to 1.2 Da and MS/MS tolerance was set to 0.6 
Da for the data from 4000 Q Trap. For Orbitrap data, the peptide tolerance was set to 
10 ppm and MS/MS tolerance was set to 0.6 Da (for MS/MS spectra acquired by 
LTQ) and 0.05 Da (MS/MS spectra acquired by Orbitrap FT mass analyzer). A fixed 
carbamidomethyl modification of cysteine and several variable modifications on 
lysine acetylation, malonylation, succinylation and carbamylation, deamidation of 
asparagine and glutamine, and methionine oxidation were applied. Only significant 
scores for the peptides defined by Mascot probability analysis 
(www.matrixscience.com/help/scoring_help.html#PBM) greater than “identity” were 
considered for the peptide identification and modification site determinations. All 
MS/MS spectra for the identified peptides with acylation modifications were manually 
inspected and validated.   
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2.3 Results 
To check whether the lack of robust deacetylase activity for SIRT4-7 is due to 
strict requirement for the peptide sequence, the activities of six human sirtuins (all 
except SIRT4, which could not be expressed in soluble forms in E. coli) were 
monitored using 16 different acetyl peptides derived from physiological substrates of 
sirtuins. Under the experimental conditions used, SIRT1-3 and 5 showed deacetylase 
activity, but SIRT6 and SIRT7 did not. All 16 peptides could be deacetylated by 
SIRT1-3, while only eight could be deacetylated slowly by SIRT5 (data not shown). A 
histone H3K9 acetyl peptide (residue 4-15, H2N-KQTAR(Kac)STGGKA-COOH)  
was one of the best substrates for SIRT1-3 and SIRT5. With this peptide, the kcat and 
Km of different sirtuins were determined (Table 2.2). The catalytic efficiency (kcat/Km) 
of SIRT5 was about 500-fold lower than that of SIRT1. 
To understand why the deacetylase activity of SIRT5 is weak, a crystal structure 
of SIRT5 in complex with a thioacetyl peptide was obtained (the corresponding acetyl 
peptide could not be crystallized with SIRT5). A buffer molecule, CHES (N-
cyclohexyl-2-aminoethanesulfonic acid), was also bound to SIRT5 (Fig. 2.2A). The 
interactions between the thioacetyl peptide and SIRT5 involved mostly backbone 
hydrogen bonding (Fig. 2.2B), similar to what was observed for Thermotoga maritime 
Sir2 (Sir2Tm), a sirtuin with robust deacetylase activity (44). Thus, it appears that the 
exact acetyl peptide sequence may not be crucial for recognition by SIRT5. 
When the SIRT5 structure was superimposed with the structure of Sir2Tm in 
complex with an acetyl peptide and NAD (PDB 2h4f) (31) (Fig. 2.3B), the positions of 
the thioacetyl lysine in SIRT5 and the acetyl lysine in Sir2Tm were almost identical in  
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Table 2.2. The kinetic parameters of four human sirtuins on H3 K9 acetyl peptide. 
Sirtuins kcat (s-1) Km for acetyl peptide (μM) kcat/Km (s-1M-1) 
SIRT1 0.039 ± 0.001 38 ± 4 1.0 x 103 
SIRT2 0.030 ± 0.001 190 ± 14 1.6 x 102 
SIRT3 0.012 ± 0.001 50 ± 9 2.4 x 102 
SIRT5 ND* ND (>750)* 2.0 
* The kcat and Km values for SIRT5 could not be determined because the V versus [S] 
plot was linear (Km was greater than the highest substrate concentration tested). Thus 
only kcat/Km value can be obtained.  
The kcat and Km values were obtained by curve-fitting the Vinitial/[E] versus [S] plot 
using KaleidaGrap. 
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Figure 2.2. The complex structure of SIRT5-tacH3K9-CHES. (A) Overall structure of 
SIRT5 in complex with an H3K9 thioacetyl peptide. The thioacetyl lysine side chain 
(green) and the CHES molecule (cyan) are shown in stick (cyan). (B) H-bonding 
interactions (dashed yellow lines) between thioacetyl peptide (green) and SIRT5 (light 
grey). 
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Figure 2.3. The structure of SIRT5 revealed an unusual acyl pocket. (A) The acyl 
pocket of SIRT5 was partially occupied by the sulfate from the CHES molecule via 
interactions with Arg105 and Tyr102. The sulfur was 4.2 Å away from the thioacetyl 
group. (B) Alignment of SIRT5-thioacetyl peptide structure (grey) and Sir2Tm-acetyl 
peptide structure (PDB 2h4f, magenta). (C) The rationale for predicting that 
malonyl/succinyl peptides could be better substrates for SIRT5. (D) SIRT5-succinyl 
peptide-NAD ternary structure showing that the succinyl group interacted with Tyr102 
and Arg105. 
 
 
 
 
 
 
 
 
 
 
 
  - 65 -
 
 
 
 
 
 
 
  - 66 -
 
 
 
 
 
 
 
 
Figure 2.4. The thioacetyl lysine binding tunnel of SIRT5. SIRT5 was bound with 
H3K9 tac peptide (green) and a buffer molecule CHES (cyan) which interacted with 
two hydrophilic residues: Y102 (red) and R105 (blue), at the bottom of the 
hydrophobic lysine binding tunnel (yellow). 
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the superimposed structures. The acetyl group in the Sir2Tm structure was surrounded 
by three hydrophobic residues, Phe48, Ile100, and Ile159. In contrast, the thioacetyl 
lysine in the SIRT5 structure entered into a hydrophobic tunnel with two hydrophilic 
residues, Y102 and R105, at the bottom (Fig. 2.4). There was extra space between 
thioacetyl group and the bottom of the tunnel, which was occupied by CHES. CHES 
formed a hydrogen bond with the polar residue Y102 and salt bridges with positively 
charged residue R105 (Fig. 2.3A and 2.4). The distance between the thioacetyl group 
and the sulfur from CHES was about 4.2 Å which equals to the length of 2-3 single 
carbon-carbon bonds (Fig. 2.3A). All those structural features of SIRT5-H3K9 
thioacetyl-CHES complex led us to the rationale presenting in Fig. 2.3C. If the acetyl 
group was elongated to a propoinyl or butyryl group, the longer chain would occupy 
the extra space which would make the longer chain bind tighter to SIRT5. Since the 
sulfate from CHES made contacts with residue Y102 and R105, if the modified lysine 
contained a sulfate group at the end, it should be a better substrate than acetyl lysine. 
However, acyl chain bearing a sulfate group at the end was physiologically irrelevant. 
Substituting of sulfate group with carboxylate will make a propionyl or a butyryl 
group into a malonyl or succinyl group, respectively, both of which are 
physiologically relevant. We predicted that malonyl or succinyl lysine peptide would 
be better substrates for SIRT5. 
In cells, the most common acyl-CoA molecules with a carboxylate group are 
malonyl-CoA and succinyl-CoA (45). Malonyl-CoA, made from acetyl-CoA by 
acetyl-CoA carboxylase in the cytosol and the mitochondria, is a precursor for fatty 
acid biosynthesis (46, 47). Succinyl-CoA is an intermediate in the Krebs cycle in the 
mitochondria. Since acetyl-CoA is used to modify proteins in cells, it is possible that 
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malonyl- and succinyl-CoA could also be used to modify proteins. Thus, H3K9 
malonyl and succinyl peptides were synthesized and tested for hydrolysis by SIRT5. 
Liquid chromatography–mass spectrometry (LC-MS) was used to monitor the 
reactions. SIRT1, 2, and 3 catalyzed the hydrolysis of the acetyl peptide, but not the 
malonyl or succinyl peptide (Fig. 2.5A-I). In contrast, with SIRT5, little hydrolysis of 
the acetyl peptide was observed, but the malonyl and succinyl peptides were 
hydrolyzed significantly (Fig. 2.5J-L). SIRT6 and SIRT7 had no detectable activity on 
the acyl peptides under the conditions tested (Fig. 2.5M-R). Thus, SIRT5 is a 
desuccinylase and demalonylase. 
What is the mechanism of SIRT5’s demalonylation and desuccinylation? If 
SIRT5 uses the same mechanism to catalyze demalonylation and desuccinylation, O-
malonyl-ADPR (O-Ma-ADPR) or O-succinyl-ADPR (O-Su-ADPR) should be 
produced. These products were indeed detected by mass spectroscopy (data not 
shown). The formation of O-Ma-ADPR and O-Su-ADPR was also detected using 32P-
NAD (Fig. 2.6A). Thus, the mechanism for SIRT5-catalyzed desuccinylation or 
demalonylation is similar to the deacetylation mechanism of Class I sirtuins. 
The kcat and Km values for SIRT5-catalyzed deacetylation, demalonylation, and 
desuccinylation were determined with three different peptide sequences (Table 2.3). 
With all three peptide sequences, the catalytic efficiencies for demalonylation and 
desuccinylation were much (29 to >1000 fold) higher than that for deacetylation 
(Table 2.3).  
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Figure 2.5. Among all human sirtuins tested, only SIRT5 catalyzed lysine 
demalonylation and desuccinylation in vitro. The enzymatic reactions were analyzed 
by LC-MS. Pink traces showed the ion intensities (10x magnified) for the masses of 
the acyl peptides (acetyl, m/z 1274.0; malonyl, m/z 1318.0; succinyl, m/z 1332.0) and 
blue traces showed the ion intensities (10x magnified) for the mass of the deacylated 
peptide (m/z 1232.0). Black traces showed the ion intensity for all masses from 100-
2000 (total ion counts or TIC). With SIRT1, hydrolysis was observed for the acetyl 
peptide (A), but not malonyl (B) or succinyl (C) peptide. With SIRT5, hydrolysis of 
the acetyl peptide was barely detectable (J) while hydrolysis of the malonyl (K) and 
succinyl (L) peptides were obvious. SIRT2 and SIRT3 only displayed deacetylation 
activity (D, G), while no activity was detected for SIRT6 and SIRT7 (M-R). 
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Table 2.3. The kinetic parameters of SIRT5 on acetyl, malonyl, and succinyl peptides 
with different sequences. 
Peptide  kcat (s-1) 
Km for peptide 
(µM) 
kcat/Km (s-
1M-1) 
deacetylation ND ND (>750) 7.8 
demalonylation 0.037 ± 0.003 6.1 ± 2.8 6.1 × 10
3 
 
H3 K9 
(KQTARKS 
TGGWW*) 
 desuccinylation 0.025 ± 0.002 5.8 ± 2.7 4.3 × 10
3 
deacetylation ND ND (>750) <2** 
demalonylation 0.014 ± 0.001 8.7 ± 1.3 1.6 × 10
3 
 
GDH K503 
(SGASEKDI 
VHSGWW*) 
 desuccinylation 0.028 ± 0.002 14 ± 4 2.0 × 10
3 
deacetylation ND ND (>750) 18 
demalonylation 0.079 ± 0.008 150 ± 40 5.2 × 10
2 
 
ACS2 K628 
(KTRSGKV 
MRRWW*) 
 desuccinylation 0.268 ± 0.051 450 ± 150 6.0 × 10
2 
* Two tryptophan residues were added at the C-terminal of the peptide to facilitate the 
detection by UV-Vis absorption during the HPLC assay. 
** No activity. The value was estimated based on the detection limit. 
ND: cannot be determined either because no activity was observed or because V 
versus [S] was linear (even the highest [S] of 750 µM used was much smaller than the 
Km). 
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A crystal structure of SIRT5 in complex with a succinyl peptide and NAD was 
obtained (Table 2.1). The structure (Fig. 2.3D) showed that the carboxylate from 
succinyl interacted with Tyr102 and Arg105, consistent with what was predicted based 
on the structure of SIRT5 with CHES bound (Fig. 2.3C). Changing Arg105 to Met or 
Tyr102 to Phe significantly increased the Km for desuccinylation (Table 2.4). Thus, 
Tyr102 and Arg105 were important for binding succinyl and malonyl groups. 
We next determined whether lysine malonylation or succinylation exists in vivo. 
Lysine succinylation was reported to occur on E. coli homoserine trans-succinylase 
(48), but lysine malonylation has not been reported. We thought that detecting SIRT5-
catalyzed formation of O-Ma-ADPR or O-Su-ADPR using 32P-NAD could be a 
sensitive assay to detect the presence of malonyl or succinyl lysine. H3K9 acetyl, 
malonyl, and succinyl peptides were incubated with SIRT5 or SIRT1 in the presence 
of 32P-NAD. The small molecule products were then separated by thin-layer 
chromatograph (TLC) and detected by autoradiography. With malonyl and succinyl 
peptides, SIRT5 consumed all the NAD molecules and new spots that corresponded to 
O-Ma-ADPR and O-Su-ADPR appeared (Fig. 2.6A). With the acetyl peptide, 
essentially no NAD was consumed by SIRT5 (Fig. 2.6A). Incubation of the acetyl 
peptide or calf thymus histones with SIRT1 produced O-Ac-ADPR (Fig. 2.6A). The 
O-Su-ADPR spot was separated from the O-Ac-ADPR and O-Ma-ADPR spots. Thus, 
SIRT5-catalyzed formation of O-Su-ADPR from the hydrolysis of succinyl peptides 
could be detected using 32P-NAD. 
The 32P-NAD assay was then used to detect whether succinyl lysine was present 
in bovine liver mitochondrial proteins because SIRT5 is localized in mitochondria (7). 
When bovine liver mitochondrial peptides were treated with SIRT5 and 32P-NAD, the  
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Table 2.4. The kinetic parameters of mutant SIRT5 on H3K9 acetyl and succinyl 
peptides. 
  kcat (s-1) Km for peptide (μM) kcat/Km (s-1M-1) 
deacetylation ND* ND (> 750)* 2 
SIRT5 
desuccinylation 0.029 ± 0.002 41 ± 11 710 
deacetylation no activity observed no activity observed - SIRT5 
H158Y desuccinylation ND* ND (> 750)* 75 
deacetylation ND* ND (> 750)* 2 SIRT5 
Y102F desuccinylation ND* ND (> 750)* 397 
deacetylation ND* ND (> 750)* 0.5 SIRT5 
R105M desuccinylation ND* ND (> 750)* 0.9 
The kcat and Km values cannot be determined because the V versus [S] plot is linear 
(Km is much greater than the highest substrate concentration tested, 750 μM). Thus 
only kcat/Km value can be obtained. 
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Figure 2.6. SIRT5 catalyzed lysine desuccinylation in vivo. (A) Succinyl lysine was 
detected in bovine liver mitochondria. SIRT5-catalyzed hydrolysis of malonyl and 
succinyl peptides could be detected using 32P-NAD, which formed 32P-labeled O-Ma-
ADPR (lane 2) and O-Su-ADPR (lane 3). No reaction occurred with acetyl peptide 
(lane 1). The formation of O-Ac-ADPR catalyzed by SIRT1 was detected (lanes 4 and 
8). O-Su-ADPR was formed when bovine liver mitochondria peptides were incubated 
with SIRT5 (lane 9), but not with SIRT1 (lane 10). The control with BSA peptides and 
SIRT5 did not generate O-Su-ADPR (lane 12). CD38-catalzyed hydrolysis of NAD 
was used to generate the standard 32P-ADPR spot (lane 13). (B) Deletion of SIRT5 
increased CPS1 succinylation level in mouse liver. CPS1 was immunoprecipitated 
from wt and SIRT5 KO livers and the level of succinylation was detected using 32P-
NAD. Synthetic acyl peptides were used to generate the reference points O-Ac-ADPR, 
O-Ma-ADPR, and O-Su-ADPR.The amount of immunoprecipitated CPS1 for lane 4-7 
is shown above. (C) The intensities of the O-Su-ADPR generated in (B) was 
quantified and compared. Numbers shown above the bars are normalized. (D) The 
CPS1 activities were measured using the liver lysates from SIRT5 wt and KO mice. 
(n=3, p<0.05) (E) and (F), MS signal intensities for CPS1 K1291 acetyl peptides from 
SIRT5 KO and wt mice. (G) and (H), MS signal intensities for CPS1 K1291 succinyl 
peptides from SIRT5 KO and wt mice. (I) and (J), MS signal intensities for a reference 
peptide from SIRT5 KO and wt mice. 
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formation of O-Su-ADPR was detected (Fig. 2.6A), suggesting that bovine liver 
mitochondrial proteins contained succinyl lysine. Control reactions with SIRT1, 
without sirtuins, or with BSA peptides did not produce O-Su-ADPR or O-Ac-ADPR 
(Fig. 2.6A). The identity of O-Su-ADPR was further confirmed by LC-MS/MS (data 
not shown). 
To identify succinylated proteins, succinyl peptides from bovine liver 
mitochondria were affinity purified using a FLAG-tagged SIRT5 (SIRT5-FLAG) and 
then identified by LC-MS/MS. Three succinylated proteins were identified: HMG-
CoA synthase 2, thiosulfate sulfurtransferase, and aspartate aminotransferase. The 
sites of succinyl modification were identified by MS/MS (data not shown). 
Furthermore, LC-MS/MS identified succinyl lysine from three commercial 
mitochondrial enzymes purified from animal tissues: glutamate dehydrogenase 
(GDH), malate dehydrogenase, and citrate synthase (data not shown). Thus, lysine 
succinylation occurs on mammalian mitochondrial proteins. 
LC-MS/MS of commercial mitochondrial enzymes identified three and two 
malonyl lysine residues on GDH and malate dehydrogenase, respectively (data not 
shown). Thus, protein lysine malonylation exists in mammalian cells.  
SIRT5 is known to regulate the activity of carbamoyl phosphate synthase 1 
(CPS1) (24). We therefore sought to test whether CPS1 was a desuccinylation target 
of SIRT5. To confirm that SIRT5’s desuccinylase functions in vivo, a SIRT5 knockout 
(KO) mouse strain was generated using standard technology. Consistent with earlier 
reports (24), CPS1 activity was 15% higher in SIRT5 wt than in SIRT5 KO mice. 
CPS1 was immunoprecipitated from wt and SIRT5 KO mouse liver and incubated 
with recombinant SIRT5 and 32P-NAD. More O-Su-ADPR was formed with CPS1 
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from SIRT5 KO mouse than with CPS1 from wt mouse (Fig. 2.6B). As a control, the 
succinylation levels on immunoprecipitated tubulin were the same in wt and SIRT5 
KO mouse. Using MS, we identified three lysine residues of CPS1 that are both 
acetylated and succinylated: Lys44, Lys287, and Lys1291 (data not shown). For 
Lys44 and Lys287, the levels of acetylation and succinylation did not change in 
SIRT5 KO mice (data not shown). For Lys1291, succinylation level increased >20-
fold in SIRT5 KO mice compared with the level in wt mice (Fig. 2.6, G and H). In 
contrast, acetylation levels of Lys1291 did not change in SIRT5 KO compared with wt 
(Fig. 2.6, E and F). Thus, SIRT5 functions as a desuccinylase in vivo. 
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2.4 Discussion 
Here we have demonstrated that SIRT5 is an NAD-dependent demalonylase and 
desuccinylase. The demalonylase or desuccinylase activity is much higher than its 
deacetylase activity. The preference for negatively charged acyl groups can be 
explained by the presence of Tyr102 and Arg105 in the active site of SIRT5, which 
are conserved in most Class III sirtuins (35). Presumably all Class III sirtuins with the 
conserved Arg and Tyr should have NAD-dependent desuccinylase and/or 
demalonylase activity.  
We showed that lysine malonylation and succinylation occur on several 
mammalian proteins. Protein lysine succinylation has been observed recently in 
bacteria (49). Protein lysine malonylation has not been reported previously. 
Acetylation occurs on numerous metabolic enzymes and regulates their activities 
in mammals and bacteria (50, 51). Given that succinyl-CoA and malonyl-CoA are 
common metabolites like acetyl-CoA (45), and all the succinylated and malonylated 
proteins we found are metabolic enzymes, it is likely that protein lysine succinylation 
and malonylation function similarly to acetylation and regulate metabolism (50, 51).  
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Chapter 3 
The Bicyclic Intermediate Structure Provides Insights into the 
Desuccinylation Mechanism of SIRT5 
3.1 Introduction 
Protein lysine acetylation is an important and reversible posttranslational modification 
which regulates protein function. Sirtuins have been widely recognized as a family of 
NAD-dependent deacetylases which remove acetyl groups from protein lysine 
residues (1, 2). Sirtuins have been shown to play crucial roles in the regulation of 
numerous cellular processes, including DNA repair, cell survival and apoptosis, and 
energy metabolism (reviewed in ref. 2, 3). They have been implicated in human health 
and diseases, including lifespan extension (4, 5), cancers (6-9), neurodegenerative 
diseases (10-13), and metabolic diseases (14, 15).   
Extensive biochemical and structural studies have uncovered the deacetylation 
mechanism (2, 16, 17). Upon the binding of both acetylated substrate and NAD, the 
nicotinamide of NAD was released first; the carbonyl oxygen of acetyl group then 
attacks the C1’ position of nicotinamide ribose, forming the alkylamidate 
intermediate; the ribose 2’-OH deprotonated by the enzyme attacks the amidate at the 
carboxyl carbon, generating the 1’-2’-cyclic intermediate, followed by the hydrolysis 
of a water molecule, producing 2’-O-acetyl-ADP-ribose (2’- OAADPr) which can be 
non-enzymatically isomerized into 3’-OAADPr. The absolutely conserved histidine 
residue among the sirtuin family serves as a general base to deprotonate the 2’-OH 
directly or through the deprotonation of 3’-OH for attacking the 1’-O-alkyl-amidate. 
Kinetic experiments and mass spectrometry have suggested the existence of the 
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alkylamidate and the cyclic intermediates (18, 19). By using the mechanism-based 
inhibitor, thioacetyl lysine peptide, the S-alkylamidate intermediate was captured in 
Sir2Tm and SIRT3 crystals (20, 21). To date, no cyclic intermediate has been directly 
observed yet.   
Among the seven sirtuins in mammals, SIRT1-3 have been demonstrated as 
robust deacetylases, while SIRT4-7 show little or undetectable deacetylation activity 
(22-29). Compared to its high deacetylation activity, human SIRT2 has been shown to 
be a less efficient depropionylase and debutyrylase (30). These findings were coupled 
by the indentification of protein lysine propionylation and butyrylation (31). However, 
in contrast to its weak deacetylation activity, SIRT5 was identified as an efficient 
desuccinylase and demalonylase (32). Furthermore, many mitochondrial proteins were 
found to contain lysine malonylation and succinylation. Independently, Zhao and 
coworkers also identified lysine succinylation and malonylation as novel 
posttranslational modifications (33, 34).      
Among the seven human sirtuins, SIRT5 was the only one with demalonylase 
and desuccinylase activity (32). SIRT5 has been demonstrated to play a pivotal role in 
ammonium disposal by regulating the enzymatic activity of carbamoyl phosphate 
synthetase 1 (CPS1) (35). It is of great interest to develop SIRT5-specific inhibitors to 
expand its cellular function and to explore therapeutic applications. The unique 
activity of SIRT5 enabled us to develop thiosuccinyl peptide as mechanism-based 
inhibitor specific for SIRT5 (36). 
 Here, together with the SIRT5-succinyl peptide-NAD ternary complex 
structure (PDB code: 3RIY) representing the Michaelis-Menten complex, I am able to 
delineate the desuccinylation reaction in SIRT5 crystals step by step by providing two 
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new structures of the SIRT5 complex: one is a complex with the succinyl lysine 
peptide, representing the enzyme-substrate binding step; the other is a complex with 
the 1’,2’-cyclic intermediate that represents the enzyme-intermediate II step. To our 
knowledge, this is the first piece of evidence supporting the existence of the 1’,2’-
bicyclic intermediate. This intermediate structure also suggests that thiosuccinyl 
peptide iinhibits SIRT5 by forming a stalled bicyclic intermediate at the active site.  
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3.2 Experimental Procedures 
Protein Cloning, Expression, and Purification. Truncated SIRT5(34-302) was cloned, 
using TOPO and Gateway cloning technology (Invitrogen Corp., Carlsbad, CA) into 
pDEST-F1 for expression, expressed in E. coli and purified as previously described 
(37). Purified Protein was dialyzed into crystallization buffer (20 mM Tris, pH 8.0, 20 
mM NaCl, 5% glycerol), concentrated to 16 mg/mL, flash frozen by liquid nitrogen, 
and stored at -80 °C for crystallization.  
Protein Crystallization. Histone H3K9 succinyl or thiosuccinyl peptides [4- KQTAR 
(suc or tsuK) STGGKA-15] were used for crystallization. SIRT5-peptide mixtures 
were prepared at a 1:20 protein:peptide molar ratio and incubated for 30~60 min on 
ice. The final protein concentration was 10 mg/mL. Crystals were grown by the 
method of hanging drop vapor diffusion. The SIRT5-H3K9 succinyl peptide co-
crystals were grown in the condition of 16% PEG 4K, 6% Glycerol at 18 °C, while the 
SIRT5-H3K9 thiosuccinyl peptide co-crystals were grown in the condition of 30% 
PEG 10K, 0.1 M TRIS, pH8.5 at room temperature.  
Data Collection and Structure Determination. SIRT5-H3K9 succinyl co-crystals were 
soaked in the cryoprotectant solution (18% PEG4K, 15% Glycerol) at room 
temperature immediately before data collection. To obtain the intermediate structure, 
SIRT5-H3K9 thiosuccinyl co-crystals were soaked in the cryoprotectant solution (30% 
PEG10k, 0.1 M TRIS, pH8.5, 15% Glycerol) with 10 mM NAD for 0.5-16 hours at 
4 °C, and flash frozen in liquid nitrogen for data collection. All the X-ray diffraction 
data were collected at the CHESS (Cornell High Energy Synchrotron Source) A1 or 
F1 station. The data were processed using the programs HKL2000 (38). The two 
structures of SIRT5 complexes were solved by molecular replacement using the 
  - 89 -
program Molrep from the CCP4 suite of programs (39). The SIRT5-H3K9 succinyl 
peptide-NAD structure (PDB code: 3RIY) served as the search model. Refinement and 
model building were performed with REFMAC5 and COOT from CCP4. The X-ray 
diffraction data collection and structure refinement statistics are shown in Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  - 90 -
 
 
Table 3.1. Crystallographic data collection and refinement statistics. 
 SIRT5-sucH3K9 SIRT5-bicyclic intermediate 
Data collection 
Space group P212121 P212121
Cell dimensions 
        a, b, c (Å) 52.69, 67.03, 157.63 52.40, 66.76, 156.86 
        α, β, γ (°) 90, 90, 90 90, 90, 90
Resolution (Å) 50-2.00 50-1.70
Rsym or Rmerge (%) 9.4 (48.4) 7.1 (45.8)
I / σI 88.6 (3.9) 214.0 (9.6) 
Completeness (%) 99.6 (97.4) 98.5 (93.5) 
Redundancy 6.8 (6.1) 6.3 (3.3)
 
Refinement 
Resolution (Å) 50-2.00 50-1.70
No. reflections 39242 61666
Rwork / Rfree (%) 22.38 /27.61 19.90/24.65 
No. of protein residues  550 550
No. of  ligand/ion 
        Succinyl 2 2
        NAD -- 2
        Zn 2 2
No. of water 100 354
R.m.s deviations 
       Bond lengths 0.047 0.025
       Bond angles (°) 2.10 2.23
Numbers showed in the parentheses are for the highest resolution shell. 
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3.3 Results 
Overall structure of SIRT5 with H3K9 succinyl peptide 
Histones have been reported as physiolocial substrates for several mammalian 
sirtuins (40-43). Previously, H3K9 peptide was found to be one of the best in vitro 
substrates for all the mammalian sirtuins (32). Biochemical data suggested that SIRT5 
shared the mechanism of dessuccinylation similar to that of deacetylation by other 
sirtuins (32). Herein, we set out to obtain structural insights to elucidate the 
desuccinylation mechanism of SIRT5 by co-crystallizing SIRT5 with a 12-mer H3K9 
peptide (4-KQTAR(Ksuc)STGGKA-15) containing succinylated lysine 9. The crystal 
is in the P21212 space group with two SIRT5 molecules in an asymmetric unit. The 
NAD-stabilizing loop was partially disordered with residues 71-74 (or 65-74 in the 
other SIRT5 molecule) invisible in the structure.  
At least three residues on each side of the succinyl lysine of H3K9 peptide 
were visible in the structure. The binding pattern of the succinyl H3K9 peptide to 
SIRT5 was the same as that of acetyl peptides to other sirtuins (44, 45). The succinyl 
H3K9 peptide formed an anti-parallel β sheet with one loop from the Zn-binding 
domain and the other loop from the Rossmann fold domain (Fig. 3.1A). This β sheet 
was stabilized by the main-chain hydrogen bonds from the enzyme and substrate 
peptide. The structural alignment within the three SIRT5 structures: SIRT5-ADPR, 
SIRT5-tacH3K9 and SIRT5-sucH3K9, suggested that the interactions within the β 
sheet drove the Zn-binding domain to rotate clockwise to the Rossmann domain, 
resulting in SIRT5 having moved from an inactive open state to an active close state 
upon the substrate binding (Fig. 3.1B). This movement was independent of the 
interactions made by the acylated lysine side chain, since the zinc-binding domain in  
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Figure 3.1. The complex structure of SIRT5-sucH3K9. (A) Three hydrophobic 
residues (Phe223, Leu227 and Val254) of SIRT5 (grey) defined the entrance of the 
substrate lysine (magenta). (B) Substrate peptide binding caused the Zn-binding 
domain (colored) to rotate clockwise to the Rossmann fold domain (grey).  
 
 
 
 
 
 
 
 
 
 
 
  - 93 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
open close
B
  - 94 -
the SIRT5-tacH3K9 structure moved to the same extent as that in the SIRT5-sucH3K9 
structure (Fig. 3.1B). 
At the entrance of the lysine binding pocket, we found that the lysine residue 
was surrounded by three hydrophobic residues from SIRT5, F223, L227 and V254 
(Fig. 3.1A), which are highly conserved within the sirtuin family. Although these three 
residues are distant in the primary sequence, they were close enough to form a small 
triangle structurally, and helped to define the entrance of the acylated lysine of the 
substrate. 
Comparison between SIRT5 with H3K9 succinyl peptide and other sirtuins 
Other studies have reported that acetyl lysine was surrounded by all 
hydrophobic residues (44). In SIRT5, however, two non-hydrophobic residues, Tyr102 
and Arg105, are positioned in the deep end of the succinyl lysine binding pocket, and 
interact with the succinyl group, which implied the specific recognition of the 
negatively charged acyl group by SIRT5 (Fig. 2A) (32). SIRT5 harbored a larger acyl 
lysine binding pocket than did SIRT3, due to the replacement of a smaller residue 
Ala86 of SIRT5 compared to Phe180 of SIRT3 (Fig. 3.2B). In the alignment, Phe180 
of SIRT3 was only 1.4 Å away from the succinyl group in SIRT5, which implied that 
the SIRT5 A86F mutant could hinder succinyl group from interacting with Tyr102 and 
Arg105 (Fig. 3.2D). Therefore, this mutant should display decreased desuccinylation 
activity. This should be similar to the de-propionylation of sirtuins (46). The structural 
alignment also showed that the succinyl lysine peptides bound to the same place as did 
acetyl lysine peptide in other sirtuins (Fig. 3.2C).  
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Figure 3.2. The structural features of SIRT5 suggested that SIRT5 was optimized for 
desuccinylation. (A) Surface representation of SIRT5’s succinyl lysine binding pocket 
(grey), which consisted of several hydrophobic residues (yellow sticks) and two non-
hydrophobic residues Tyr102 and Arg105 which interacted and stabilized the succinyl 
lysine (magenta). (B) Surface representation of SIRT3’s acetyl lysine binding pocket 
(grey). This pocket consisted of all hydrophobic residues (yellow sticks). The residue 
F180 lies at the upper right bottom of the pocket. (C) Structural alignment among 
SIRT5 (magenta), SIRT3 (cyan), Sir2Tm (yellow) and yHst2 (green) showed that the 
succinyl lysine in SIRT5 bound to the same place as acetyl lysine in other sirtuins. (D) 
Detailed view of SIRT5 and SIRT3 alignment: the smallest distance from succinyl 
group to Phe180 of SIRT3 was 1.4 Å, indicating that phenylalanine would cause 
spatial hindrance for succinyl lysine.  
 
 
 
 
 
 
 
 
  - 96 -
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
SIRT5          SIRT3           Sir2Tm       yyHst2   
A86
F180 
A86 
Y102
R105sucK9 
H158 
I142
V220 
C D
 
  - 97 -
Comparison between SIRT5-sucH3K9 and SIRT5-sucH3K9-NAD 
Biochemical studies have demonstrated that the acetyl substrate bound to 
sirtuins first, followed by NAD binding (47). This ordered binding manner ensured 
that NAD adopted a productive conformation which led to the completion of the 
deacetylation reaction (48). Previously, we were able to capture the Michaelis-Menten 
complex of SIRT5 with both succinyl lysine peptide and NAD bound. In this structure, 
the NAD binding loop was ordered and stabilized NAD at the active site (Fig. 3.3A). 
As described above, binding of succinyl lysine substrate caused the movement 
between the two domains of SIRT5. The alignment of Cα atoms between the succinyl 
lysine peptide-bound structure and the Michaelis-Menten complex structure of SIRT5 
yielded a RMS of 0.357, arguing that NAD did not cause any further movement 
between the two domains of SIRT5 (Fig. 3.3A).    
Similar to NAD in other sirtuins, the nicotinamide group of NAD inserted into 
the C pocket of SIRT5 where it formed hydrogen bonds with the side chain of the 
invariant residue Asp143 and the main chain nitrogen of Ile142, as well as two water 
molecules (Fig. 3.3B). Those interactions caused the carboxylamide of nicotinamide to 
rotate off the plane of pyridine ring, which activated the cleavage of nicotinamide. 
Residue Phe70 from the NAD binding loop paralleled roughly to the pyridine ring but 
almost perpendicular to the ribosyl ring, making room for the nicotinamide release. 
The other two conserved residues, Gln140 and Asn141, formed hydrogen bonds via 
their side chains with 3’ and 2’ –OH of N-ribose, respectively (Fig. 3.3B). The 
carboxyl oxygen of the succinyl group formed an additional hydrogen bond with 3’-
OH of the ribose. Those interactions collectively positioned N-ribose in an orientation 
which favored the cleavage of nicotinamide. The catalytic residue His158 did not  
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Figure 3.3. NAD bound to SIRT5 in a productive conformation in the Michaelis-
Menten complex. (A) The alignment between SIRT5-H3K9 succinyl peptide and 
SIRT5-Michaelis complex indicated that NAD binding did not change the overall 
structure of SIRT5, except that the NAD binding loop (magenta) was ordered in the 
Michaelis complex structure. (B) The nicotinamide and N-ribose of NAD made 
extensive interactions with SIRT5 (grey cartoon) and water molecules (red dot) to 
enable the cleavage of nicotinamide.  Residues were shown in grey, hydrogen bonds 
in yellow, succinyl lysine in magenta, NAD in green. Phe70, almost perpendicular to 
N-ribose, formed Van der Waals interactions with the nicotinamide ring. His158 did 
not interact with NAD. The carboxyl oxygen of the succinyl group made a hydrogen 
bond with N-ribose.  
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contact with NAD at this stage, consistent with the finding that catalytically deficient 
yeast HST2 mutant had little effect on nicotinamide release rate (49).     
Structure of SIRT5-bicyclic intermediate II 
Extensive studies have established the mechanism of deacetylation of sirtuins, 
which includes the formation of two intermediates: the O-alkylamidate intermediate I 
and the bicyclic intermediate II (2, 16, 17). Thioacetyl lysine peptides have been 
reported as inhibitors for sirtuins with deacetylase activities, because the 
corresponding intermediate can be stalled at the active site, resulting in much lower 
turn-over rate (19). Because SIRT5 is the only mammalian sirtuin that prefers 
succinyl, we designed a thiosuccinyl lysine peptide as a SIRT5-specific inhibitor. 
Indeed, it was demonstrated that it inhibited SIRT5 with an IC50 of 5 µM while it did 
not inhibit SIRT1, 2, or 3, even at 100 μM (36). In order to better understand the 
mechanism of SIRT5’s desuccinylation, we co-crystallized SIRT5 with thiosuccinyl 
H3K9 peptide, then soaked the co-crystals in 10 mM NAD for 0.5-16 hours. The S-
alkylamidate intermediate I was unable to be captured in the crystals while all the data 
sets contained the S-bicyclic intermediate II. The 14 hour NAD-soaking structure was 
determined to 1.7 Å resolution (Fig. 3.4). In the crystal, the thiosuccinyl lysine peptide 
reacted with NAD and formed the bicyclic intermediate II. Other groups have captured 
the S-alkylamidate intermediate I in Sir2Tm and SIRT3 (19, 20) via similar 
approaches. In our structure, however, when the S-alkylamidate intermediate I was 
fitted into the density, the 2’-OH group was only 1.7 Å from the succinyl carbon, 
which is similar to the distance of a carbon-oxygen single bond (about 1.4 Å) (Fig. 
3.4C). The cyclic intermediate II fitted the density better when the 2’ OH group 
attacked the carbon of the succinyl group (Fig. 3.4D). An average carbon-sulfur single  
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Figure 3.4. The complex structure of SIRT5-bicyclic intermediate II. (A) The 2Fo-Fc 
omit electron density map (1σ) showing the S-cyclic intermediate II. (B) The Fo-Fc 
map (2σ) showing the same view as in (A). (C) The possible fitting of the S-
alkylamidate intermediate I. 2Fo-Fc map (blue) contoured at 1.0 σ and Fo-Fc map 
(green) contoured at 3 σ. However, the distance between 2’-OH oxygen and carbon of 
succinyl group was only 1.72Å. (D) The bond length in the S-cyclic intermediate II; 
(E) the interactions that S-cyclic intermediate II made.  
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bond is 1.8 Å, and those bonds in the intermediate II were in great agreement with that 
(Fig. 3.4D). The cyclic intermediate II was stabilized by extensive hydrogen bonds 
from both the backbone and the side-chains as well as hydrophobic interactions (Fig. 
3.4E). Tyr102 and Arg105 specifically recognized succinyl group. The catalytic 
residue H158 formed a hydrogen bond with 2’-OH of N-ribose, and deprotonated it to 
promote the nucleophilic attack of succinyl carbon by 3’-OH. Residue Gln140 was 
absolutely conserved in all mammalian sirtuins, formed a hydrogen bond with N-
ribose via the backbone oxygen, and played a key role in positioning the N-ribose 
during the reaction. The highly conserved residues, Val221, interacted with and 
stabilized the lysine side chain via a hydrogen bond of its backbone oxygen with ε-N 
of lysine. The benzyl ring of Phe70 paralleled with N-ribose ring and formed π-π 
hydrophobic interactions, thus stabilizing the intermediate at the active site. All those 
interactions stabilized and positioned the cyclic intermediate at the active site in a 
conformation that is favorable for the turn-over.  
Comparison between SIRT5-bicyclic intermediate and the Michaelis intermediate 
Compared to the Michaelis-Menten complex structure of SIRT5, the NAD 
binding loop of the cyclic intermediate remained almost the same, indicating that the 
nicotinamide cleavage and intermediate formation did not interfere ADPR binding and 
stabilization (Fig. 3.5A). However, residue Phe70 on the NAD binding loop adopted 
two different orientations. In the Michaelis-Menten complex structure, Phe70 was 
perpendicular to the ribosyl ring of NAD, which was proposed to favor nicotinamide 
escape (20). In the cyclic intermediate structure, Phe70 paralleled the ribose face, 
which prevented the base-exchange reaction of nicotinamide from generating NAD 
(Fig. 3.5A). Compared to the ADPR in the SIRT5-ADPR structure (PDB code:  
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Figure 3.5. The comparison between the bicyclic intermediate II (cyan) and the 
Michaelis-Menten complex (magenta) of SIRT5. (A) The NAD binding loop was the 
same in two structures, except that residue Phe70 was almost perpendicular to each 
other. In the intermediate structure, Phe70 was parallel to the nicotinamide ribose, 
while in the Michaelis-Menten structure, Phe70 was perpendicular to the ribose. (B) 
After the cleavage of nicotinamide, the ribose flipped to the succinyl lysine, 
repositioning the two phosphates to facilitate the formation of the intermediate. (C) 
The lysine side chain was rotated about 18º to form the intermediate. 
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2B4Y), the cyclic intermediate exhibited the same conformation in the ADPR 
fragment, while NAD in the Michaelis-Menten complex oriented in a different way, 
especially in the phosphates and N-ribose part (Fig. 3.5B). Those differences 
suggested that NAD first bound to SIRT5 in the conformation which favored the 
cleavage of nicotinamide, and then after nicotinamide released, the N-ribose flipped 
and rotated to some degree which favored the nucleophilic attack of the succinyl 
group. The lysine side chain was rotated about 18º to form the intermediate, which 
caused corresponding movement of the succinyl group except that the carboxylate of 
succinyl group remained the contacts with Tyr102 and Arg105 (Fig. 3.5C). 
Comparison between SIRT5-bicyclic intermediate and SIRT3-intermediate I  
Previously, kinetic studies and Mass Spectrometry have demonstrated the 
existence of the alkylamidate and 1’, 2’-bicyclic intermediates (18, 19). In 2008, 
Hawse et al. trapped a S-alkylamidate intermediate in Sir2Tm of 2.5 Å resolution 
using thioacetyl peptide (20). That was the first direct observation of an alkylamidate 
intermediate. Later, a similar alkylamidate intermediate was obtained in human 
SIRT3, which aligned well with the intermediate in Sir2Tm (21). We captured a 1’, 2’-
bicyclic intermediate II in human SIRT5 crystal and solved the structure to 1.7 Å 
resolution. The ADP-ribose part of the alkylamidate and cyclic intermediates 
superimposed well except the orientation of N-ribose (Fig. 3.6). Compared to the 
alkylamidate intermediate I in SIRT3, the ribose plane rotated some degree toward the 
succinyl group, which favored the nucleophilic attack of 2’-OH to the succinyl carbon. 
This suggested that the nucleophilic attack of 2’-OH of the ribose caused 
conformational change in the ADP-ribose.  
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Figure 3.6. The structural alignment between SIRT5-bicyclic intermediate II and 
SIRT3-alkylamidate intermediate I showed that the N-ribose changed its conformation 
to facilitate the nucleophilic attack of 2’-OH to the succinyl carbon.  
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3.4 Discussion 
SIRT5 was recently identified as a novel desuccinylase and demalonylase (32), 
which is different from the typical sirtuin function of deacetylase. Biochemical studies 
suggested that SIRT5 used a mechanism similar to deacetylation to remove a malonyl 
or succinyl modification from lysine residues. Previously, two alkylamidate 
intermediates were shown to be trapped in the Sir2Tm and human SIRT3 structures 
(20, 21), supporting the ADPR-peptidyl-imidate mechanism of deacetylation. Our 
study demonstrates, for the first time, that a bicyclic intermediate can be directly 
observed in crystals, providing one more piece of evidence that sirtuins utilize the 
ADPR-peptidyl-imidate mechanism to remove acyl group from substrate lysine. The 
desuccinylation mechanism of SIRT5 is summarized in Fig. 3.7. Upon the formation 
of the Michaelis-Menton complex, the oxygen atom of the carboxyl from succinyl 
group forms a hydrogen bond with 3’-OH of nicotinamide ribose of NAD (Fig. 3.7 I). 
The two residues of SIRT5, Gln140 and Asn141, which are invariant among sirtuins, 
form additional hydrogen bonds with 3’-OH and 2’-OH of the ribose, respectively. 
The carboxyl amide of nicotinamide interacts with the absolutely conserved Asp143 
and the highly conserved Ile142. Those interactions collectively force the 
nicotinamide into a high energy conformation which subsequently causes the cleavage 
of nicotinamide and generates the transient ionic intermediate (Fig. 3.7 II). It is likely 
that this oxocarbonium-ion intermediate is stabilized via hydrogen bond between 3’-
OH of the ribose and the catalytic residue His158 and via π-π hydrophobic interactions 
between the ribose ring and residue Phe70 (Fig. 3.7 II). The release of nicotinamide 
leads to the rotation of the nicotinamide ribose (Fig. 3.5B), which disrupts the 
interactions between the ribose and residue Gln140 and Asn41  
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Figure 3.7. The structure-based desuccinylation mechanism of SIRT5. SIRT5 residues 
are colored in blue. (I) Upon the binding of a succinylated lysine peptide and an NAD, 
the extensive interactions between NAD and peptide & enzyme drive NAD to a 
productive conformation which results in the cleavage of nicotinamide. (II)The release 
of nicotinamide generates a positively charged oxacarbonium-ion transient 
intermediate which is stabilized by interactions with His158 and Phe70. (III) Upon the 
leave of nicotinamide, the ribose rotates to expose 1’-carbon to the carboxyl oxygen of 
succinyl group for nucleophilic attack, followed by the formation of the O-
alkylamidate intermediate. (IV) The 2’-OH of the ribose attacks the carboxyl carbon 
of succinyl group and generates the 1’, 2’-bicyclic intermediate which is additionally 
stabilized by hydrogen bond between 3’-OH and main chain oxygen of Gln140. (V 
and VI) The bicyclic intermediate is hydrolyzed into free lysine and succinyl-O-ADP 
ribose. 
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(Fig. 3.7 II). The new conformation of nicotinamide ribose favors the attack of the 
carboxyl oxygen of succinyl group, producing the ADPR-peptidyl-imidate 
intermediate (Fig. 3.7 III), followed by the attack of 2’-OH to the carboxyl carbon of 
succinyl group to form the bicyclic intermediate (Fig. 3.7 IV). The bicyclic 
intermediate is further hydrolyzed into a free lysine and a succinyl-O-ADP ribose (Fig. 
3.7 V and VI). 
We were unable to obtain the alkylamidate intermediate and the thiosuccinyl-
O-ADP-ribose product, even though we soaked co-crystals of SIRT5-thiosuccinyl 
H3K9 peptide in 10 mM NAD at 4 ºC from 0.5 to 16 hours. Regardless of the NAD 
soaking time we tested, we could only trap the bicyclic intermediate at the active site. 
This is quite different from the soaking experiments with Sir2Tm or SIRT3, which 
could generate the alkylamidate intermediate and thioacetyl-O-ADP-ribose product 
with relatively short and long soaking time in NAD, respectively (20, 21). This 
suggests that, although sirtuins share similar mechanism to remove acyl groups from 
modified lysines, different sirtuins may preferentially stabilize different intermediates 
at the active site. SIRT5 favors the bicyclic intermediate as the more stable specie than 
the alkylamidate one. Additionally, the type of acyl group may affect the stability of 
those two intermediates.  
Similar to lysine acetylation/deacetylation, lysine malonylation/demalonylation 
and succinylation/desuccinylation should be important in regulating protein functions. 
To date, only carbamoyl phosphate synthetase 1 (CPS1) has been identified as a 
desuccinylation substrate of SIRT5 (32). Further exploration of SIRT5’s novel 
substrates awaits future effort. The thiosuccinyl peptide is a mechanism-based 
inhibitor for SIRT5, which specifically inhibits SIRT5 with the IC50 value of 5 μM 
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(36). This is about 5-fold lower than that of suramin, generally accepted as an inhibitor 
for SIRT5. The structural study presented here will facilitate the design of specific 
inhibitors to fully characterize SIRT5’s cellular functions as well as to search for more 
physiological substrates of SIRT5. Additionally, SIRT5 inhibitors can be potential 
drugs for therapeutic applications.  
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Chapter 4 
Plasmodium falciparum Sir2A Preferentially Hydrolyzes Medium and 
Long Chain Fatty Acyl Lysine2 
4.1 Introduction 
Sirtuins are a family of enzymes known as nicotinamide adenine dinucleotide (NAD)-
dependent deacetylases (1, 2). They regulate a variety of biological processes, 
including transcription and metabolism (3, 4). Plasmodium falciparum (P. falciparum) 
contains two sirtuins, PfSir2A and PfSir2B (5). It was shown that these two sirtuins 
regulate the expression of surface antigens to evade the detection by host immune 
surveillance (6, 7). Thus, inhibiting these sirtuins may help fight malaria. It was 
thought that PfSir2A and PfSir2B achieve this physiological function by deacetylating 
histones. In vitro studies on PfSir2A showed that it has deacetylase activity (8). 
However, the activity was weak compared to several other sirtuins (9), such as human 
SIRT1 and yeast Sir2. It was also reported that PfSir2A had ADP-ribosyltransferase 
activity (8). However, several reports questioned whether the ADP-ribosyltransferase 
activity of sirtuins was physiologically relevant since the measured activity of several 
sirtuins was weak (10, 11). 
In addition to acetylation, lysine propionylation and butyrylation have been 
                                                 
2 This work was published in ACS Chemical Biology on Oct. 21, 2011 online. 
Permission of reusing it in this dissertation was granted by ACS chemical Biology, 
copyright 2011 American Chemical Society. I was a co-first author, responsible for 
the protein purification, crystallization, and diffraction data collection and processing, 
structure solving of PfSir2A complexes. Some of the figures have been rearranged for 
readers’ convenience.   
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reported as posttranslational modifications that occur on proteins, including histones 
(12-14). Many fatty acyl-CoA molecules exist in cells as metabolic intermediates. If 
the shorter chain fatty acyl CoA molecules (acetyl-CoA, propionyl-CoA, and butyryl-
CoA) are used as acyl donors to modify proteins, it is possible that longer chain fatty 
acyl-CoA molecules can also be used to modify protein. Given that PfSir2A’s 
deacetylase activity is weak, we set out to investigate whether longer chain fatty acyl 
lysine can be accepted as better substrates by PfSir2A.        
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4.2 Experimental Procedures  
Cloning, Expression, and Purification of PfSir2A. PfSir2A gene was custom 
synthesized by Genscript. The sequence was codon optimized for overexpression in E. 
coli and cloned into pET-28a (+) vector with BamHI and XhoI restriction sites. The 
PfSir2A expression vector was then introduced into an E. coli BL21 with pRARE2. 
Successful transformants were selected by plating the cells on kanamycin (50 mg mL-
1) and chloramphenicol (20 mg mL-1) luria broth (LB) plates. Single colonies were 
selected and grown in LB with kanamycin (50 mg mL-1) and chloramphenicol (20 mg 
mL-1) overnight at 37oC. On the following day the cells were then subcultured (1:1000 
(v/v)) into a 2 L LB with kanamycin (50 mg mL-1) and chloramphenicol (20 mg mL-1). 
The cells were induced with 500 M of isopropyl β-D-1-thiogalactopyranoside (IPTG) 
at OD600 of 0.6 and grown overnight at 15oC, 200 rpm. The cells were harvested by 
centrifugation at 6000 rpm for 10 minutes at 4oC (Beckman Coulter Refrigerated Floor 
Centrifuge) and passed through an EmulsiFlex-C3 cell disruptor (AVESTIN, Inc.) 3 
times. Cellular debris was removed by centrifuging at 20000 rpm for 30 minutes at 
4oC (Beckman Coulter). The PfSir2A was then purified using gravity flow Ni-affinity 
chromatography (Sigma) and dialyzed into 25 mM Tris pH 8.0, 50 mM NaCl, 1 mM 
DTT, 10% (v/v) glycerol. The proteins were then aliquoted and kept frozen at -80oC. 
For crystallization, the His6-tag of PfSir2A was removed by overnight incubation at 
4°C with 30 unit mL-1 of thrombin (Haematologic Technologies Inc.), followed by Ni-
affinity column purification to separate the undigested PfSir2A from the digested one. 
Then, the tag-free PfSir2A was further purified by FPLC with SuperdexTM 75 column 
(Bio-rad), dialyzed into crystallization buffer (20 mM HEPES, pH 7.1, 20 mM NaCl, 
5 mM DTT, 3% (v/v) glycerol), concentrated into 10 mg mL-1, flash frozen by liquid 
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nitrogen, and stored at -80 °C for crystallization. 
Synthesis of Acyl Peptides. Solvents were purchased from Fisher Scientific unless 
otherwise specified and peptide synthesis reagents and Fmoc-protected amino acids 
and derivatives were purchased from Creosalus Inc.       
The H3K9 (NH2-KQTARK*STGGWW-COOH) backbone was prepared using 
standard solid phase peptide synthesis (SPPS) at room temperature (RT). Wang resins 
SS (100-200 mesh, 1% DVB, 10 mmole/g) were placed into a peptide synthesis vessel 
along with 5 mL of anhydrous dichloromethane (DCM) for 5 hours. The first activated 
amino acid solution was freshly prepared with 0.32 mmoles of Fmoc-W-OH, 0.32 
mmoles of O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU), 0.133 mmoles of 4-dimethylaminopyridine (DMAP), 0.64 mmoles of 
diisopropylethylamine (DIEA, added last) and an appropriate amount of anhydrous 
N,N’-dimethylformamide (DMF). The resin was incubated with the solution overnight 
at RT. The resins were then washed with DMF (5 times) before incubating with a 
cocktail of acetic anhydride, pyridine and DMF (2:1:3 ratio (v/v)) for 30 minutes to 
block remaining amino groups on the resin. Kaiser test was used to test the success of 
the coupling. Once coupling was confirmed, 20% (v/v) piperidine in DMF was used to 
remove Fmoc. All subsequent activated amino acid derivatives were freshly prepared 
with 0.24 mmoles of the amino acid, 0.24 mmole of HBTU, 0.21 mmole of N-
hydroxybenzotriazole (HOBT), 0.48 mmole of DIEA in DMF and reaction time was 2 
hours at RT.   
The lysine to be modified by different acyl groups (K*) was protected with allyl 
carbamate (Alloc) on the side chain while the N-terminal K was protected by Boc.  
After all the peptide coupling steps were done on the resin, the Alloc group was 
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removed by incubating the resin in a cocktail of DCM, morpholine (Sigma, 2.5%) and 
glacial acetic acid (5%) with a 1:1 weight ratio of the original resin and 
tetrakis(triphenylphosphine)palladium(0) for 4 hours under nitrogen. Several washes 
of 0.5% (v/v) DIEA in DCM and 0.02 M of diethyldicarbamate in DMF were carried 
out to remove the palladium. The resin was then incubated with solutions for putting 
on different acyl groups. The acylation solutions contained 0.24 mmoles of fatty acids 
of different chain lengths (acetic anhydride, butyric acid, octanoic acid, or myristic 
acid), 0.24 mmole of HBTU, 0.21 mmole of HOBT, 0.48 mmole of DIEA and DMF.  
The resin was then washed with DMF and the peptides were cleaved with a mixture of 
trifluoroacetic acid (TFA), 5% (v/v) water, 5% (w/v) phenol, 2.5% (v/v) ethanedithiol 
and 5% (v/v) thioanisole. TFA was removed from the filtered peptide solution and the 
peptides were precipitated out by the addition of ether and lyophilized. The crude 
peptides were dissolved in water and purified by HPLC (Beckman Coulter System 
Gold 125P solvent module and 168 Detector) using a TARGA C18 column (250 x 20 
mm, 10 µM, Higgins Analytical, Inc.) with mobile phase A (water with 0.1% (v/v) 
TFA) and B (acetonitrile with 0.1% (v/v) TFA) at a gradient of 20% B to 100% B in 
50 minutes and a flow rate of 10 mL/min. The peptides were monitored at 215 nm and 
280 nm and fractions were collected. LCMS (SHIMADZU LCMS-QP8000α with a 
Sprite TARGA C18 column (40 × 2.1 mm, 5 μm, Higgins Analytical, Inc.) was used 
to confirm the peptide mass and high purity fractions were lyophilized. The solvents 
used in LCMS were water with 0.1% (v/v) formic acid and acetonitrile with 0.1% 
(v/v) formic acid.  
HPLC Assay and Kinetics. Activity of PfSir2A was determined using HPLC, by 
quntifying the modified and unmodified H3K9 peptide. The reaction contained 20 mM 
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of Tris pH 8.0, 1 mM DTT, 20 µM H3K9 modified peptide, 1 mM of NAD and 1 µM 
of PfSir2A and was incubated at 37oC for 1 hour. The reaction was quenched with 1 
volume of 10% (v/v) TFA and spun down for 10 minutes at 18,000 g (Beckman 
Coulter Microfuge) to separate the PfSir2A from the reaction. The supernatant was 
then analyzed by HPLC.   
The kcat and Km values were determined using HPLC to quantify the amount of 
product formed with varying concentrations of the modified peptide with 1 mM of 
NAD, 20 mM Tris pH 8.0, 50 mM DTT, 0.5 µM of PfSir2A (butyryl, octanoyl and 
myristoyl H3K9 peptide), and 1 µM of PfSir2A was used for acetyl H3K9. Peptide 
concentration used for H3K9 acetyl and butyryl were both 2, 4, 8, 16, 32, 64, 128, and 
256 µM with an incubation time of 40 and 20 minutes, respectively. Peptide 
concentration used for H3K9 octanoyl was 1, 2, 4, 8, 16, 32, 64, and 128 µM with an 
incubation time of 15 minutes. Peptide concentration used for H3K9 myristoyl was 1, 
2, 3, 4, 5, 6, 8, and 16 µM with an incubation time of 1 minute. The stock solutions of 
the different peptides were made in different solvents. H3K9 acetyl was stored in 
water while the longer fatty acyl peptides, butyryl and octanoyl were stored in 1:1 
(v/v) DMSO:water solutions. The myristoyl peptide is especially hydrophobic and was 
stored in DMSO. If only water was used to dissolve them, the peptides would stick to 
the plastic tubes used and led to errors in the peptide concentration. The final 
concentrations of DMSO in the assays varied from 0 to 10% by volume. The quenched 
reactions were then analyzed via HPLC using a reverse phase analytical column 
(Sprite TARGA C18, 40 × 2.1 mm, 5 μm, Higgins Analytical, Inc.) with a 0% to 70% 
B gradient in 8 minutes at 1 mL/min. The acetyl peptide has a very close retention 
time to the unmodified peptide and a different column was used to separate the peaks 
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(Kinetex XB-C18 100A, 75x 4.60 mm, 2.6 um, Phenomenex). The product peak and 
the substrate peaks were both quantified and converted to initial rates, which were then 
plotted against the modified peptide concentration and fitted using the Kaleidagraph 
program.   
32P-NAD Assay. The reaction contained 50 mM Tris pH 8.0, 150 mM NaCl, 10 mM 
DTT, 60 µM H3K9 modified peptide, 0.1 µCi of 32P-NAD (American Radiolabeled 
Chemicals, ARP 0141-250 µCi) and 1 µM of Pfsir2A and was incubated at 37oC for 1 
hour. P. falciparum whole cell lysate (100 µL) was first denatured with 6 M of Urea, 
15 mM of DTT at 37oC for 15 minutes. Then it was alkylated with 50 mM of 
iodoacetamide in the dark at RT for 1 hour. The solution was then diluted so that the 
final concentration of urea was less than 0.75 M and digested with 0.1 µg/µL trypsin 
and 50 mM Tris pH 7.4, and 1 mM CaCl2 overnight at 37oC. The digest was quenched 
with 10% TFA to a final pH of 2 to 3 and desalted with a Waters C18 Sep-Pak 
column. The peptides were eluted 5 times with 1 mL of 90% ACN/0.1%TFA and 
lyophilized. The peptides were then solubilized in 50 µL of water and 1 µL was used 
in the 32P-NAD assay under conditions described above. The reaction was incubated at 
37oC for 15 minutes and 1 µL of the reaction mixture was spotted onto a polyester 
backed silica plate (100 µm thick, Waters). After the spots were dried, the plate was 
run for 6 cm in 30:70 (v/v) 1M ammonium bicarbonate:95% ethanol. The plate was 
dried and exposed overnight in a PhosphorImaging screen (GE Healthcare). The signal 
was detected using a STORM860 phosphorimager (GE Healthcare).    
Crystallization, Data Dollection, and Structural Refinement. PfSir2A was mixed with 
H3K9 myristoyl peptide at the protein:peptide molar ratio of 1:10, diluted into 3 mg 
mL-1 with crystallization buffer, and incubated on ice for 30-60 minutes. Crystals were 
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grown at room temperature with hanging drop vapor diffusion method at the condition 
of 16% (w/v) PEG 3350, 0.1 M NaF, 7% (v/v) formamide. PfSir2A-H3K9 myristoyl 
co-crystals were soaked in the cryoprotectant solution (18% (w/v) PEG 3350, 0.1 M 
NaF, 10% (v/v) formamide, 15% (v/v) glycerol) with 10 mM NAD for 2-10 minutes at 
room temperature immediately before data collection. All data were collected at 
CHESS (Cornell High Energy Synchrotron Source) F2 station. The data were 
processed using the programs HKL2000 (24). Using the program Molrep from the 
CCP4 suite of programs (25), the structures were solved by molecular replacement 
with PfSir2A-AMP structure (PDB code: 3JWP) as the search template. Refinement 
and model building were performed with REFMAC5 and COOT from CCP4. The X-
ray diffraction data collection and structure refinement statistics were shown in Table 
4.1. 
Atomic coordinates and structure factors were deposited in the Protein Data 
Bank under accession codes 3U3D and 3U31 for PfSir2A-myrH3K9 and PfSir2A-
myrH3K9-NAD, respectively. 
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Table 4.1. Crystallographic data collection and refinement statistics. 
 PfSir2A-myrH3K9 PfSir2A-myrH3K9-NAD
Data collection 
Space group P21212 P21212
Cell dimensions 
       a, b, c (Å) 32.51, 103.33, 105.51 32.17, 102.73, 105.18
       α, β, γ (º) 90, 90, 90 90, 90, 90 
Resolution (Å) 50-2.40 50-2.20 
Rsym or Rmerge (%) 14.9 (75.3) 12.9 (74.8) 
I /σI 23.83 (1.75) 24.7 (2.21) 
Completeness (%) 98.5 (97.2) 99.9 (99.9) 
Redundancy 8.2 (4.4) 6.7 (5.0) 
 
Refinement 
Resolution (Å) 50-2.40 50-2.20 
No. reflections 18972 23688
Rwork / Rfree (%) 22.38 /27.61 20.24/24.65 
No. of protein residues  263 263
No. of  ligand/ion 
        Myristoyl 1 1
        NAD -- 1
        Glycerol 1 1
        Zn 1 1
No. of water 25 75
R.m.s deviations 
       Bond lengths 0.047 0.024
       Bond angles (º) 2.10 2.07
Numbers showed in the parentheses are for the highest resolution shell. 
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4.3 Results 
The PfSir2A gene was de novo synthesized. The protein was expressed in E. coli 
and affinity purified to near homogeneity. For substrates, we synthesized histone H3 
peptides bearing acetyl, butyryl, octanoyl, and myristoyl groups on Lys9. To facilitate 
the detection of the peptides by ultra-violet (UV) light absorption, two Trp residues 
were added to the C-terminal of the peptides. A high-pressure liquid chromatography 
(HPLC) assay was used to monitor the activity of PfSir2A on these different acyl 
peptides. Interestingly, all four acyl peptides could be hydrolyzed (Fig. 4.1). The 
butyryl, octanoyl and myristoyl peptides could be hydrolyzed more efficiently than the 
acetyl peptide. The myristoyl peptides appeared to be hydrolyzed most efficiently.  
To quantitatively compare the activity of PfSir2A on different acyl peptides, 
kinetic studies were carried out. The kinetics data (Table 4.2) suggested that acetyl 
H3K9 peptide was the least efficient substrate among the four acyl peptides tested, 
with a kcat/Km of 26 s-1M-1. The kcat/Km value for deacetylation was comparable to that 
reported by Sauve and coworkers (9). The butyryl, octanoyl, and myristoyl peptides 
were hydrolyzed with much higher catalytic efficiencies. In particular, the catalytic 
efficiencies for the hydrolysis of myristoyl peptide were more than 300-fold higher 
than that for the hydrolysis of acetyl peptide. The Km value for the myristoyl peptide 
was lower than 1µM (PfSir2A was saturated with 2 µM of the myristoyl peptide. The 
Km value could not be accurately determined because of the detection limit at low 
substrate concentrations). The enzymology data demonstrated that PfSir2A 
preferentially hydrolyzes medium and long chain fatty acyl lysine. 
To understand the structural basis for PfSir2A’ preference for longer chain fatty 
acyl groups, we co-crystallized PfSir2A with an H3K9 myristoyl peptide to generate 
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Figure 4.1. PfSir2A could hydrolyze medium and long chain fatty acyl lysine more 
efficiently than acetyl lysine. (A) Overlaid HPLC traces showing PfSir2A-catalyzed 
hydrolysis of different fatty acyl lysine peptides. Acyl peptides were used at 20 µM, 
PfSir2A at 1 µM, and NAD at 500 µM. The corresponding synthetic peptide without 
any acyl lysine modification (H3K9WW unmodified) was used as the control to 
indicate the position of the hydrolysis product formed.  
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Table 4.2. Kinetics data for PfSir2A on different acyl peptides. 
substrate kcat (s-1) Km for peptide (µM) kcat/Km (s-1M-1) 
H3K9 acetyl 0.001 ± 0.0002 39 ± 9 2.6 x 101 
H3K9 butyryl 0.001 ± 0.0002 8  ± 1 1.6 × 102 
H3K9 octanoyl 0.001 ± 0.004 1.2 ± 0. 3 9.2 × 102 
H3K9 myristoyl 0.01± 0.002 <1.0a >1.0 × 104 
a. The Km value cannot be accurately determined due to the detection limit when 
substrate concentration was lower than 1 µM. 
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the PfSir2A-H3K9 myristoyl complex. The co-crystal was then soaked briefly in an 
NAD solution to obtain a ternary complex of PfSir2A with H3K9 myristoyl peptide 
and NAD. The structures were solved using molecular replacement with the deposited 
PfSir2A structure PDB 3JWP as the search model. The overall structure of PfSir2A 
was similar to other sirtuins, containing a small Zn-binding domain and a large 
Rossmann fold domain (Fig. 4.2A) (15-18). The two substrates, H3K9 myristoyl 
peptide and NAD, bound to the clefts between the two domains. This binding mode of 
the two substrates was similar with the reported ternary complex structures of other 
sirtuins. For instance, the peptide substrates of the Thermotoga maritima Sir2 
(Sir2Tm, PDB 2H4F, one of the first sirtuin ternary complex structureswith both NAD 
and acetyl peptide bound) and PfSir2A superimposed well (Fig. 4.2B) (19). The 
interactions between PfSir2A and H3K9 myristoyl peptide mainly came from main 
chain hydrogen bonds (Fig. 4.2C), in agreement with other studies of sirtuins (19). 
Compared with the structure without any acyl peptide bound (PDB 3JWP), the binding 
of H3K9 myristoyl peptide to PfSir2A caused the Zn-binding domain to rotate 
clockwise to the Rossmann fold domain, so that PfSir2A moved from an open state to 
a close state which is similar to that observed in Sir2Tm (Fig. 4.2D) (19). However, 
different from Sir2Tm, PfSir2A had a long open hydrophobic tunnel that 
accommodated the myristoyl group (Fig. 4.2E). The hydrophobic tunnel was 
surrounded by several hydrophobic residues (Ile45, Trp56, Ile77, Ile80, Ile84, Ile90, 
Val116, Val135, Phe136, Ile178, and Leu181). This structure feature suggested that 
PfSir2A was optimized for recognizing fatty acyl groups. 
The enzymology and structural data led to the hypothesis that PfSir2A may 
function to remove medium and long chain fatty acyl groups in malaria parasite. 
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Figure 4.2. Structural basis for the recognition of myristoyl lysine by PfSir2A. (A) 
Overall structure of PfSir2A. The Fo-Fc map at 1.6σ shows the H3K9 myristoyl 
peptide (green) and NAD (yellow) at the active site. (B) The structural alignment 
between Sir2Tm (blue) and PfSir2A (grey). The positions of H3K9 myristoyl peptide 
and NAD in PfSir2A were similar to the positions of acetyl peptide and NAD in 
Sir2Tm. (C) Hydrogen bonding interactions between the H3K9 myristoyl peptide 
(green) and PfSir2A (grey). (D) Structural alignment between PfSir2A-AMP (cyan, 
PDB code: 3JWP) and PfSir2A-myrH3K9 showed that the binding of the substrate 
peptide myrH3K9 drove PfSir2A from an inactive open state to an active close state. 
(E) PfSir2A had a long open hydrophobic tunnel which accommodated fatty acyl 
groups. PfSir2A surface representation: grey; myristoyl lysine: green; hydrophobic 
residues: orange. 
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Protein lysine myristoylation has been reported to occur on several mammalian 
proteins (20, 21). To test whether malaria parasite proteins have medium or long chain 
fatty acyl modifications on lysine residues, a sensitive assay was developed to detect 
the presence of fatty acyl lysine in malaria parasites. With the use of 32P-NAD, the 
formation of fatty acylated ADP-ribose (ADPR) in PfSir2A-catalyzed defatty 
acylation of synthetic acyl peptides can be detected after thin-layer chromatography 
(TLC) separation and autoradiography. Longer chain fatty acyl ADPR species were 
more hydrophobic and thus moved faster than shorter chain fatty acyl ADPR species 
(Fig. 4.3). Notably, most NAD molecules were consumed when octanoyl and 
myristoyl peptides were incubated with PfSir2A, while there were still NAD 
molecules left when acetyl and butyryl peptides were incubated with PfSir2A. This 
observation confirmed the kinetic studies that octanoyl and myristoyl peptides were 
more efficient substrate for PfSir2A. When total protein extracts of malaria parasites 
were incubated with 32P-NAD and PfSir2A, the formation of a longer chain fatty acyl 
ADPR was detected. The position of the fatty acyl ADPR was similar to that formed 
the reactions with synthetic octanoyl and myristoyl peptides, suggesting that fatty acyl 
group on P. falciparum proteins should have a similar chain length. The intensity of 
the fatty acyl ADPR spot was weak, suggesting that the concentration of the fatty acyl 
peptide in our P. falciparum protein extract was low. However, we could repeatedly 
detect this spot using the 32P-NAD assay. In addition, compared with the negative 
control without PfSir2A, the intensity for the acetyl ADPR spot did not increase. 
Therefore, PfSir2A’s deacetylase activity could not be detected using P. falciparum 
protein extract, but the activity of removing longer fatty acyl groups could be detected. 
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Figure 4.3 32P-NAD assay could detect the presence of medium or long chain fatty 
acyl lysine modifications on P. falciparum proteins. PfSir2A were incubated with 32P-
NAD and synthetic peptides bearing different acyl modifications. Negative controls 
were reactions without PfSir2A or peptides. The reactions were resolved by TLC and 
detected by autoradiography. With P. falciparum peptides (last two lanes), the acyl 
ADPR spot formed was similar to the C8-C14 acyl ADPR, suggesting that such fatty 
acyl groups were present and could be removed by PfSir2A. 
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4.4 Discussion 
In summary, our enzymology and structural data demonstrated that PfSir2A 
was more efficient at removing medium and long chain fatty acyl groups than acetyl 
groups from peptides. Although it is known that other sirtuins can also hydrolyze 
propionyl and butyryl lysine, but the activity is typically weaker than the hydrolysis of 
acetyl lysine (22, 23). Therefore, our work demonstrates for the first time that longer 
fatty acyl lysines can be the preferred substrate for a sirtuin. The biochemical data 
suggest that P. falciparum proteins contain such fatty acyl lysine modifications, which 
can be removed by PfSir2A in vitro. The data imply that the biological function of 
PfSir2A may be achieved by its activity of removing medium and long chain fatty acyl 
groups. The detailed structures of the fatty acyl groups and the abundance of such 
modifications in comparison to the well-known acetyl lysine modification await future 
studies. The finding that PfSir2A could remove longer fatty acyl groups suggests that 
other sirtuins, especially those that have weak or no deacetylase activity, may also 
have this activity. sirtuins should therefore be called “NAD-dependent deacylases”, 
instead of “NAD-dependent deacetylases”. The discovery of a robust activity for 
PfSir2A will also facility the development of PfSir2 inhibitors, which may have 
therapeutic value in treating malaria. 
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Chapter 5 
Prenylation and Membrane Localization of Cdc42 are Essential for 
Activation by DOCK7 
5.1 Introduction 
Rho family of GTPases plays pivotal roles in many cellular processes, including cell 
polarity, motility, vesicular trafficking, cell-cycle progression, and gene expression (1-
4). Their functions largely depend on their cellular localization, which are determined 
by the posttranslational modification of the C-terminal CAAX motif (where C 
represents cysteine, A is any aliphatic amino acid, and X is any amino acid) (5, 6). The 
prenyltransferase catalyzes the modification of CAAX motifs and adds a farnesyl or 
geranylgeranyl isoprenoid lipid tail to the cysteine residue (7). For instance, both 
Cdc42 and Rac1 are geranylgeranylated. The attached lipid tail of the GTPase inserts 
into the cellular membrane and brings the GTPase to the subcellular compartments 
where it engages its regulators: GEFs (Guanine nucleotide Exchange Factors), GAPs 
(GTPase Activating Proteins), and GDIs (Guanine nucleotide Dissociation Inhibitors). 
GEFs promote the exchange of GDP for GTP, therefore activating Rho GTPases. 
GAPs enhance the hydrolysis of GTP and inactivate GTPases. Rho GDIs sequester 
GDP-bound Rho GTPases in the cytosol by inhibiting nucleotide exchange (8-10). 
 Two families of GEFs have been identified for Rho GTPases: the classical Dbl 
family (11) and the recently discovered DOCK180 family (12-14). The Dbl family 
consists of ~70 members, all of which contain two conserved domains, the Dbl 
homology (DH) and the pleckstrin homology (PH) domain (15-18). The DH domain is 
the catalytic domain for nucleotide exchange, while the PH domain has been 
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demonstrated to interact with the plasma membrane (19, 20). The mammalian 
DOCK180 family contains 11 members, DOCK1-11 (with DOCK180 as DOCK1) 
(21, 22). One of the major features of the DOCK180 family is that all members 
possess two DOCK homology regions, DHR1 and DHR2, which share no sequence 
similarity with the PH and DH domains of the Dbl family, respectively. The DHR1 
domain shares low homology with the C2 motif and associates with the cellular 
membrane (23). The DHR2 domain is necessary and sufficient to exchange GDP for 
GTP on GTPases (22). Recently, our laboratory has identified a limit C-terminal 
portion of DHR2, designated DHR2c, which exhibited full GEF activity (24).  
 DOCK180 family members have been shown to activate Rac1 and/or Cdc42, but 
not RhoA. These are classified into four subfamilies: DOCK-A to DOCK-D 
subfamilies. The DOCK-A subfamily contains DOCK1, 2, and 5, while the DOCK-B 
subfamily consists of DOCK3 and DOCK4, all of which are Rac1-specific GEFs. 
DOCK9-11 comprise the DOCK-D subfamily and are Cdc42 specific GEFs. DOCK6-
8 fall within the DOCK-C subfamily, which are capable of activating both Rac1 and 
Cdc42 (25). The Barford group has solved two complex structures: Cdc42 with 
DOCK9-DHR2 and Rac1 with DOCK2-DHR2, which not only elucidated the 
mechanism by which DOCK180 family members activate Rho GTPases but also shed 
light on the specificity of DOCK180 proteins and their points of contact (26, 27). Two 
residues at positions 27 and 56 of Rac1 and Cdc42 are key determinants of specificity 
for nucleotide exchange by DOCK180 proteins. Wu et al. have shown that residues 
from the α10 helix of DOCK180 proteins play a key role in the selectivity of Rac1 or 
Cdc42 (24).  
 DOCK-C subfamily members have been proposed to activate both Rac1 and 
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Cdc42. However, using traditional in vitro GEF assays, no robust GEF activity has 
been observed for DOCK-C members, such as DOCK6 and DOCK7 (27-30). 
Therefore it is of interest to investigate whether DOCK7 is a Rac1-specific or Cdc42-
specific GEF. In vivo the DOCK-C members are important in the regulation of 
neuronal cell development. DOCK6 has been reported to regulate the early 
development of neurite formation of neuron cells (28, 31). In addition, DOCK7 has 
been demonstrated to be involved in axon formation by activating Rac1 and Cdc42 
(29, 30). Also, DOCK7 was shown to interact with the TSC1/TSC2 complex, which 
implies that DOCK7 may act as a regulator of the mTOR complex (32).  
 To better understand the molecular basis of DOCK7’s function, I set out to 
investigate the biochemical characteristics of DOCK7. Here I present data to show that 
DOCK7 showed undetectable GEF activity toward non-prenylated Rac1 or Cdc42 in 
solution, but exhibited robust activation of prenylated Rac1 and Cdc42 in a model 
liposome system. In addition, I identify two key residues in DOCK7 which convey 
GTPase exchange specificity and the mutations of these two residues shift the 
DOCK7-DHR2 activity profile. Additionally, I show that DOCK7 possesses a distal 
site that is distinct from the nucleotide exchange site and preferentially binds to the 
active forms of Rac1 and Cdc42, which helps to recruit DHR2 to the membrane 
surface to enhance the rate of GTPase nucleotide exchange.  
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5.2 Experimental Procedures 
Plasmid Constructs. The coding region of DOCK7 (accession No. from EMBL: 
DQ118679) was ligated into the Bac-to-Bac baculovirus expression vector 
pFastBacTMHT C (Invitrogen). The cDNAs encoding the DOCK truncation constructs: 
DHR2 (amino acid 1433-1992), DHR2s (amino acid 1530-1970), and DHR2c (amino 
acid 1688-1992), were inserted into pFastBacTMHT C vector for insect cell expression. 
Also, DHR2 and DHR2s were cloned into ppSUMO vector for E.coli expression. 
DHR2c was inserted into pET28b for E.coli expression. DOCK7-DHR2c mutants 
were generated with the QuickChange site-directed mutagenesis kit (Stratagene). The 
full-length Cdc42 and Rac1 were cloned into the pFastBacTMHT C, pGEX-4T-1, and 
pET28a vectors.  
Preparation of Insect Cell Expressed Proteins. All the target proteins cloned into 
pFastBacTMHT C vector were expressed in Spodoptera frugiperda (Sf21) cells. The 
expression of Cdc42 and Rac1 were carried out at Kinnakeet Biotechnology 
(Midlothian, VA), and the purification was performed as described previously (10). 
All the DOCK7 constructs were expressed in 0.5 L Sf21 cell suspension culture for 3 
days after virus infection. The cells were pelleted down by centrifuging at 500g at 4°C 
for 5 minutes and stored at -80°C for purification. The cell pellet was suspended in 20 
mL lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 2% Triton X-100) with protease 
inhibitor cocktail (Roche) and disrupted by Dounce homogenization. The lysate was 
spun down at 9000g for 20 minutes at 4 °C. The supernatant was incubated with Ni-
NTA agarose beads (Qiagen) for 30 minutes at 4°C. The beads were washed with 20 
volumes of washing buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% CHAPS, 30 
mM imidazole), and protein was eluted with 10 mL elution buffer (50 mM Tris, pH 
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8.0, 150 mM NaCl, 0.1% CHAPS, 200 mM imidazole). The fraction containing the 
target protein was concentrated to 3 mL. 
Preparation of E.coli Expressed Proteins. All the DOCK7 constructs which were 
cloned either into the pET28 or ppSUMO vector, and the Cdc42 and Rac1 constructs 
which were cloned into either pGEX or pET28 vector, were expressed in Escherichia 
coli. A single colony of E.coli BL21(DE3) or Rosetta 2 strain containing the target 
plasmid was inoculated in 5 mL LB medium with 50 µg/mL kanamycin or 100 µg/mL 
carbenicillin (RPI) overnight at 37°C. The overnight culture was subsequently 
transferred to 1 L 2xYT medium with antibiotic and inoculated at 37 °C until OD600 
reached 0.6, followed by induction with 0.1 mM isopropyl 1-thio-β-D-
galactopyranoside (IPTG) (RPI) at room temperature for overnight. Bacteria were 
harvested by centrifugation at 4000g for 10 minutes at 4 °C and stored at -80 °C for 
future purification. The His6-tagged DOCK7 pellets were suspended in lysis buffer (20 
mM Tris, pH 8.0, 500 mM NaCl, 20 mM imidazole) with protease inhibitor cocktail 
(Roche), and lysed by sonication on ice. The lysates were centrifuged at 20000 g for 
30 minutes at 4 °C, and the resulting supernatants were incubated with Ni-NTA 
agarose beads for 30 minutes at 4°C. The beads were extensively washed with 
washing buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 40 mM imidazole), and the 
proteins were eluted with 20 mL elution buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 
200 mM imidazole). The proteins were then concentrated in 50 mM Tris, pH 8.0, 50 
mM NaCl. For His6-tagged Cdc42 and Rac1, bacterial pellets were suspended in 25 
mL lysis buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 5 mM MgCl2, 100 µM GDP, 20 
mM imidazole) with protease inhibitor cocktail (Roche), and lysed for 1 hour 
incubation on ice with 150 mg lysozyme (Sigma), 45 mg deoxycholic acid (Sigma), 
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and DNase I powder (Roche). The following purification procedure was the same as 
for His6-tagged DOCK7 proteins, except that the buffers contained 5 mM MgCl2. For 
GST-tagged Cdc42 and Rac1, bacterial pellet was suspended in 25 mL lysis buffer (50 
mM Tris, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 100 µM GDP, 1 mM DTT) with 
protease inhibitor cocktail, and lysed for 1 hour as described above. The lysate was 
spun down and the supernatant was incubated with glutathione sepharose beads 
(Amersham Bioscience) at 4 °C for 1 hour. The beads were washed with washing 
buffer (50 mM Tris, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM DTT). The protein 
was eluted with 20 mL elution buffer (50 mM Tris, pH 8.0, 10 mM reduced 
glutathione, 5 mM MgCl2). Both His6- and GST- tagged Cdc42 and Rac1 were 
changed to storage buffer (50 mM Tris, pH 7.5, 50 mM NaCl, 2 mM MgCl2, 0.5 mM 
DTT), concentrated to 200 µM, flash froze by liquid nitrogen, and stored at -80 °C for 
assays. 
Preparation of Liposomes. The lipids used in this study were purchased from Avanti 
Polar Lipids. The model liposomes contained 35% phosphatidylethanolamine, 35% 
cholesterol, 25% phosphatidylserine, and 5% phosphatidylinositol. Two approaches 
were used to prepare liposomes for different purposes. Rapid solvent exchange was 
used to make large liposomes that can be pelleted by low speed centrifugation (33). 
For in vitro GEF assays, small lipid vesicles with 1 µm diameter were prepared by 
extrusion using Avanti mini-extruder. 
Nucleotide-loading of Cdc42 and Rac1. Cdc42-MantGDP, Rac1-MantGDP, Cdc42-
GTPγS, and Rac1-GTPγS were prepared by incubating insect cell-expressed 
prenylated Cdc42 or Rac1 with 40-fold excess MantGDP or 10-fold excess GTPγS in 
the buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 5 mM MgCl2, 0.1% CHAPS) with 10 
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mM EDTA for 1.5 hour on ice, followed by the addition of 20 mM MgCl2 and a 0.5 
hour incubation to quench the excess EDTA. The excess nucleotide was removed by 
Ni-column purification as described above. The eluted nucleotide-loaded Cdc42 and 
Rac1 were changed to the buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 5 mM MgCl2, 
0.1% CHAPS) and concentrated to 20 µM. 
In vitro GEF Assays. Nucleotide exchange on Cdc42 or Rac1 was monitored by the 
fluorescence change of Mant nucleotide with an exciting wavelength of 360 nm and an 
emission wavelength of 440 nm. Using a Varian Clary Eclipse fluorimeter, all samples 
were continuously stirred at 25 °C in TBSM buffer (50 mM Tris, pH 7.5, 50 mM 
NaCl, 5 mM MgCl2) with 1 μM Mant nucleotide. For non-prenylated Cdc42 or Rac1, 
GST-Cdc42 or GST-Rac1 was added to the cuvette followed by the addition of 
DOCK7-DHR2s or DHR2c. For prenylated Cdc42 or Rac1, His6-tagged Cdc42 or 
Rac1 was first incubated with liposomes for 15 minutes at room temperature, then 
added to a cuvette to make a final liposome concentration of 20 µM. DOCK7-DHR2s 
or DHR2c was added to initiate the exchange. To check whether the active form of 
Cdc42 or Rac1 had an effect on the activation of Cdc42 or Rac1 by DOCK7, DHR2s 
or DHR2c was incubated with Cdc42-GTPγS or Rac1-GTPγS for 15 minutes at room 
temperature before it was added to the reaction. 
Liposome Centrifugation Assays. To assay the binding preference of DOCK7 to the 
three different forms of prenylated Cdc42 or Rac1 (nucleotide-free, GDP bound, GTP 
bound), 0.2 nmol insect cell expressed Cdc42 or Rac1 was incubated with 100 µL of 1 
µM lipids prepared by rapid solvent exchange for 10 minutes at room temperature, 
loaded with no nucleotide, GDP, or GTPγS, and centrifuged at a maximum speed on a 
table top centrifuge for 10 minutes. The supernatant was removed and lipid pellet was 
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resuspended in 40 µL TBSM buffer, followed by a 30 minutes incubation at room 
temperature with 160 nmol DOCK7-DHR2s or DHR2c. The mixture was spun down, 
and the supernatant and lipid pellet were examined by SDS-PAGE to check the 
partitioning of DOCK7 between supernatant and pellet. The negative control only 
contained lipids and either DOCK7-DHR2s or DHR2c (without Cdc42 or Rac1). 
GST-Cdc42/Rac1 Pull-down Assays. To check the binding of DOCK7 to non-
prenylated Cdc42 or Rac1, 0.4 nmol E.coli expressed GST-Cdc42 or GST-Rac1 was 
prebound to 15 µL glutathione sepharose beads in the presence of 10 mM EDTA. The 
negative control only contained beads and either DOCK7-DHR2s or DHR2c (without 
GST-Cdc42 or GST-Rac1). To prepare GST-Cdc42 or GST-Rac1 preloaded with GDP 
or GTPγS, excess GDP or GTPγS was added to the samples and incubated for 15 
minutes at room temperature, followed by the addition of 20 mM MgCl2 and 320 nmol 
DOCK7-DHR2s or DHR2c, and incubated for 1 hour at 4 °C. The beads were spun 
down, washed with TBSM for 3 times, and examined by SDS-PAGE. 
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5.3 Results 
 All the DOCK180 family members have a C-terminal domain of approximately 
500 amino acids, termed the DHR2 domain, which is necessary and sufficient for GEF 
activity (22). Other studies have demonstrated that the recombinant protein of the full 
length DHR2 domain of DOCK180 or DOCK9 was not stable in solution, whereas a 
slightly shorter version of DHR2 was sufficiently stable for GEF assays and 
crystallization (24, 26). Therefore, we designed four different constructs of DOCK7 
for overexpression in insect cells to characterize the biochemical features of DOCK7 
(Fig. 5.1A). The full length DOCK7 contains 1992 residues that includes 22 residues 
beyond the DHR2 domain. These C-terminal 22 residues were included in the 
construct designated DHR2. DHR2s lacked the N-terminal 87 residues of DHR2 as 
well as the C-terminal 22 residues. DHR2c was designed to test whether it represted a 
limit functional domain as in the case of DOCK180. The DHR2s and DHR2c 
constructs were successfully expressed and purified in insect cells (Fig. 5.1B). As 
previously described, GST-tagged Rac1 and Cdc42 recombinant proteins were used 
for the GEF assays (Fig. 5.1B). We also expressed His6-tagged Rac1 and Cdc42 in E. 
coli as the counterparts of His6-tagged Rac1 and Cdc42 expressed in insect cells (Fig. 
5.1B). The Cdc42 and Rac1 present in the membrane fraction of insect cells are 
prenylated whereas the GTPases present in the cytosolic fractions are not prenylated 
(Fig. 5.1B). The prenylated recombinant Cdc42 has been shown to bind to both insect 
cell membranes and reconstituted model liposomes (10).  
      We first tested whether DOCK7-DHR2s or DHR2c could activate Cdc42 or 
Rac1. By monitoring the fluorescence changes that accompany the binding of Mant 
nucleotide to the GTPase, no detectable activation of GST-Cdc42 or GST-Rac1 was  
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Figure 5.1. DOCK7 and GTPase proteins (A) Schematic representation of the 
DOCK7 and DHR2 constructs that were examined in this study. (B) SDS-PAGE and 
Colloidal Blue staining of wild type proteins used in this study.  
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observed in the presence of DOCK7-DHR2s in solution (Fig. 5.2). DHR2c could not 
initiate noticeable activation of either GST- Cdc42 or GST-Rac1 (data not shown). 
However, the addition of EDTA caused a significant nucleotide exchange in GST-
Cdc42 (Fig. 5.2A), and the Rac1-specific GEF DOCK1-DHR2c could promote the 
Mant-GDP loading of GST-Rac1 (Fig. 5.2B). To rule out that the GST tag might 
present an obstacle for the interaction between DOCK7-DHR2s or DHR2c and Cdc42 
or Rac1, the replacement of GST-Cdc42 and GST-Rac1 by His6-Cdc42 and His6-
Rac1, respectively, still resulted in no detectable activation by DOCK7-DHR2s or 
DHR2c (data not shown). These data were consistent with the findings of another 
DOCK-C member, DOCK6-DHR2, which showed no activation of Cdc42 or Rac1 
using the conventional fluorescence assay (27). However, a modest activation of Rac1 
and Cdc42 by DOCK7-DHR2 was detected by using a more sensitive radioactive 
assay for GDP-GTP exchange (29, 30). Those observations were inconclusive as to 
whether DOCK-C members were the GEFs for both Cdc42 and Rac1. 
 Rho GTPase proteins consist of a large GTPase domain in the N-terminus and a 
polybasic region (PBR) followed by the CAAX motif in the C-terminus. Both PBR 
and CAAX motif are important for Rho GTPases’ cellular functions (5, 6). The 
positively charged Arg and Lys residues of PBR have been proposed to facilitate the 
binding of Rho GTPases to cellular membranes. The attached prenylation tail to the 
cysteine residue of the CAAX motif can insert into membranes where GTPases are 
able to engage their regulators and effectors. Since DOCK7-DHR2s or DHR2c could 
not promote significant activation of either Cdc42 or Rac1 in solution, I further tested 
the prenylated Cdc42 and Rac1 in a model liposome system.  
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Figure 5.2. DOCK7-DHR2s/c did not activate non-prenylated GST-Cdc42/Rac1. (A) 
DHR2s (160 nM) (red) showed no ability to stimulate the GDP-to-MantGDP 
exchange of E.coli expressed GST-Cdc42 (200 nM). 10 mM EDTA (blue) was added 
as the positive control. No GEF was added as a negative control. (B) In contrast to 
DOCK1-DHR2c (200 nM) (blue), which stimulated the GDP-to-MantGDP exchange 
of E.coli expressed GST-Rac1 (200 nM), DOCK7-DHR2s (160 nM) (red) showed no 
activation on GST-Rac1. Even in the presence of 20 µM liposome DOCK7-DHR2s 
(160 nM) (dark purple) showed no activation toward the E.coli-expressed His6-Cdc42 
(C), nor toward the cytosolic fraction (non-prenylated) of Cdc42 expressed in insect 
cells (D). 
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 The insect cell-expressed geranylgeranylated Cdc42 was incubated with 
liposomes at room temperature to allow for membrane binding by Cdc42. Cdc42 was 
observed to bind Mant-GDP upon the addition of DOCK7-DHR2s (Fig. 5.3A). 
Similarly, insect cell expressed Rac1 was activated upon the addition of DOCK7-
DHR2s (Fig. 5.3B). However, non-prenylated Cdc42 suspended in the same liposome 
mixture did not undergo nucleotide exchange in the presence of DOCK7-DHR2s (Fig. 
5.2C). Furthermore, the cytosolic fraction (non-prenylated) of insect cell expressed 
Cdc42 did not exhibit any significant nucleotide exchange by DOCK7-DHR2s (Fig. 
5.2D). These data demonstrate that the prenylation and membrane localization of 
Cdc42 and Rac1 were essential for the activation by DOCK7. Additionally, DOCK7-
DHR2c could activate both Cdc42 and Rac1 to the same extent as DHR2s, supporting 
a model whereby DOCK7-DHR2 also contained a limit C-terminus which is necessary 
and sufficient to activate Rho GTPases (Fig. 5.3A). Finally, the activation of Cdc42 by 
DHR2s was dose-dependent (Fig. 5.3C).  
The recently solved complex structures of Cdc42-DOCK9 and Rac1-DOCK2 
shed some light regarding the DOCK-GTPase specificity (26, 27). Phe56 of Cdc42, 
and Trp56 of Rac1, are the key specificity residues for the recognition by DOCK 
proteins. Substitution of Phe56 of Cdc42 with tryptophan displayed a dramatic 
decrease in the activation by DOCK9, while the W56F mutant of Rac1 showed much 
lower efficiency in coupling to DOCK180. Phe56 of Cdc42 interacted with residues 
Leu1941, Gln1949, and Gly1950 of DOCK9 (Fig. 5.4A). Among them, Leu1941 is 
conserved in the DOCK-D (Cdc42-specific) subfamily; Gln1949 is invariant in both 
the DOCK-C and DOCK-D subfamilies; while Gly1950 is absolutely conserved in all 
the DOCK180 family members. Methionine in the DOCK-A/B (Rac-specific) and  
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Figure 5.3. DOCK7-DHR2s/c activated prenylated Cdc42 and Rac1 suspended in the 
model liposomes. In the presence of 20 µM liposomes, either DHR2s (50 nM) (red) or 
DHR2c (50 nM) (blue) was added to initiate the GDP-to-MantGDP exchange of insect 
cell-expressed prenylated Cdc42 (200 nM) (A) or Rac1 (200 nM) (B). No GEF was 
added in the negative control. (C) The activation of Cdc42 by DOCK7-DHR2s 
displayed a dose-dependent behavior.  
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Figure 5.4. Specificity switches of DOCK7 between Cdc42 and Rac1. (A) Sequence 
comparison between DOCK subfamilies A, C, and D members: DOCK1, DOCK7, and 
DOCK9, respectively. Numbering is for DOCK7 sequence. (B)SDS-PAGE and 
Colloidal Blue staining of DOCK7-DHR2c wild type and mutant protein tested in this 
figure. (C) Mutation of Methionine 1875 of DHR2c to Leucine increases its GEF 
activity toward Cdc42; while mutation of Glutamine 1878 of DHR2c to Asparagine 
decreases its GEF activity toward Cdc42.  
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DOCK-C subfamilies corresponds to residue Leu1941 in DOCK9; whereas asparagine 
in the DOCK-A/B (Rac-specific) subfamily corresponds to residue Gln1949 in 
DOCK9. These alignments collectively suggested that the combination of leucine and 
glutamine in the DOCK-D subfamily accounted for the specificity for Cdc42, and that 
the combination of methionine and asparagine in the DOCK-A/B subfamily was 
responsible for the specificity for Rac. Thereby, the combination of methionine and 
asparagine in DOCK7 offered an explanation for its dual GEF function for both Cdc42 
and Rac1. The M1875L mutant of DOCK7 was proposed to shift it to a Cdc42-
specific GEF while the N1878Q mutant was expected to exhibit Rac-specific GEF 
activity. The DOCK7-DHR2c M1875L and N1878Q mutants were expressed and 
purified (Fig. 5.4B). As predicted, M1785L exhibited a more robust GEF activity 
toward Cdc42 than wild-type DHR2c. Conversely, the N1878Q mutant showed almost 
no GEF activity toward Cdc42. The V1885A mutant of DHR2c was used as a negative 
control as it has been shown to be catalytically defective, and as predicted, it showed 
no GEF activity (Fig. 5.4C).  
 DOCK7-DHR2s and DHR2c showed similar GEF activity, but differed in their 
abilities to bind to the different states of GTPases in terms of nucleotide association. 
When prenylated Cdc42 was bound to larger model liposomes which can be pelleted 
at a low speed, and treated with EDTA, GDP, or GTPγS, DHR2s bound to nucleotide-
free and Cdc42-GTPγS with higher affinity than to Cdc42-GDP (Fig. 5.5A). 
Additionally, compared to nucleotide-free Cdc42, more DHR2s was pelleted by 
Cdc42-GTPγS, suggesting that DHR2s exhibited a slight preference for GTPγS bound 
Cdc42 (Fig. 5.5A). Similar behavior was observed with geranylgeranylated Rac1 (Fig. 
5.5A). However, DHR2c acted as a typical GEF and bound preferentially to the  
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Figure 5.5. DOCK7-DHR2s, but not DHR2c, preferentially bound to the active forms 
of Cdc42 and Rac1. (A) DHR2s was pelleted with EDTA-treated and GTPγS-treated, 
prenylated Cdc42 (left panel) or Rac1 (right panel) that was accociated with 
liposomes. (B) DHR2c was only pelleted with EDTA-treated, prenylated Cdc42 (left 
panel) or Rac1 (right panel). (C) DHR2s was pulled down with E.coli-expressed 
GTPγS-treated GST-Cdc42 and GST-Rac1, while DHR2c was not able to bind to 
either of these GTPγS-loaded proteins (D). 
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nucleotide-free forms of its cognate GTPases (Fig. 5.5B). These data argue that the 
limit DHR2c domain was responsible for binding the inactive forms of the GTPases 
for nucleotide exchange, while the extra N-terminal portion of DHR2s was involved in 
the recruitment of the active forms of these proteins. These findings were further 
supported by the results of the GST-Cdc42/Rac1 pull-down assays. When non-
prenylated E. coli-expressed GST-Cdc42/Rac1 was bound to glutathione beads, and 
treated by EDTA, GDP, or GTPγS, DHR2s was only pelleted with Cdc42/Rac1-
GTPγS (Fig. 5.5C). No detectable amount of DHR2c was pulled-down by any form of 
GST-Cdc42 or Rac1 (Fig. 5.5D). These data were also in good agreement in that no 
detectable GEF activity of DHR2s or DHR2c was observed on GST-tagged Cdc42 or 
Rac1 (Fig. 5.2). 
 SOS (Son of sevenless), a Ras-specific GEF, has been shown to possess a second 
distal GTPase binding site, which is distinct from the catalytic site. This distal site is 
responsible for binding the active form of Ras (i.e. GTP bound Ras) and regulating 
GEF exchange rates resulting in a positive feedback activation of Ras (34). The 
binding of Cdc42/Rac1-GTP by DHR2s implied that DHR2s might have a similar 
distal regulatory site that interacts with Cdc42/Rac1-GTP, representing a potential 
positive feedback loop in the activation of Cdc42/Rac1. Consistent with this, Cdc42, 
preloaded with Mand-GDP, showed accelerated binding of GTPγS upon the addition 
of DHR2s to the model liposome system (Fig. 5.6A). It appears that the Cdc42-GTPγS 
enhanced the nucleotide exchange as the reaction proceeded. The addition of the 
active Cdc42-GTPγS to the inactive Cdc42 caused an increase in Mant fluorescence, 
suggesting that the exchange rate may be influenced by the recruitment of DOCK7-
DHR2s to the liposomes via the membrane-associated Cdc42- GTPγS (Fig. 5.6B). 
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Figure 5.6. DHR2s seems to activate Cdc42 via a positive feedback loop. (A) 200 nM 
Cdc42 preloaded with MantGDP was assayed for nucleotide exchange in the presence 
of 160 nM DHR2s, 50 µM GDP or GTPγS. (B) 250 nM Cdc42 was assayed for 
nucleotide exchange in the presence of 16 nM DHR2s, 1 µM MantGDP, with or 
without the addition of 100 nM Cdc42-GTPγS. 
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5.4 Discussion 
 The DOCK180 family members have been demonstrated to regulate multiple 
cellular processes, including cell migration, cell phagocytosis, cytoskeleton 
reorganization (35-40), and neuronal differentiation (29-31). They function as 
upstream activators (GEFs) of Cdc42 and/or Rac1 from the Rho family of small 
GTPases which are critical players in actin dynamics. The recent structural and 
functional studies on the DOCK9-Cdc42 and DOCK2-Rac1 complexes have 
elucidated the mechanism of how DOCK180 members activate their cognate GTPases, 
and provided insights to the specificity of how DOCK180 proteins recognize 
GTPases. Both the Rac1-specific DOCK-A member and the Cdc42-specific DOCK-D 
member shares the same mechanism to activate Rac1 and Cdc42, respectively. It is 
reasonable to propose that DOCK-C subfamily members utilize the same mechanism, 
given that replacing the catalytic residue Val1885 of DOCK7-DHR2c with alanine 
abolished its GEF activity (Fig. 5.4C).  
 The GEF activity and specificity of the DOCK-A and the DOCK-D subfamilies 
have been well studied (22, 41). However, little is known about the biochemical 
characteristics of the DOCK-C subfamily members, such as DOCK7, mainly because 
DOCK7 displayed little GEF activity toward Cdc42 or Rac1 in solution using standard 
in vitro GEF assays. Interestingly, I found that the DHR2 domain (i.e. the DHR2c and 
DHR2s constructs) exhibited robust GEF activity toward prenylated Cdc42 or Rac1 in 
the presence of model liposomes by monitoring changes in the fluorescence of Mant 
nucleotide upon their binding to the GTPases (Fig. 5.2). DOCK7, at nanomolar 
concentrations, stimulated the activation of GTPases on liposomes, whereas it showed 
no GEF activity even when assayed at micromolar concentrations in solution. This  
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Figure 5.7. Theoretical model of Cdc42/Rac1 activation by DOCK7 via a possible 
positive feedback loop. In solution, DOCK7-DHR2s could not stimulate the activation 
of Cdc42 or Rac1, whereas when assayed on liposomes, DOCK7-DHR2s initiated 
nucleotide exchange on Cdc42 or Rac1. The addition of Cdc42-GTPγS accelerated the 
rate of nucleotide exchange.  
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suggests that DOCK7 is sensitive to the lipidation and membrane localization of 
GTPases (Fig. 5.7). Our observations were mirrored by studies on the Ras GEF, SOS, 
which showed that the farnesylation of Ras was necessary to further promote SOS-
mediated nucleotide exchange (42, 43). 
 The position 56 of Cdc42 and Rac1 (phenylalanine and tryptophan, respectively) 
has been identified as the key residue that is responsible for the specific recognition by 
DOCK180 proteins (24, 27). The side chain of residue 56 of Cdc42 or Rac1 inserts 
into a binding pocket present within DOCK180-related proteins and makes contacts 
with the side chains of residues in the pocket, including Leu1941 and Gln1944 of 
DOCK9 for Cdc42, or Met1529 and Asn1532 of DOCK2 for Rac1. The replacement 
of Met1524 of DOCK1 can restore about 25% activation of Rac1 W56F mutant (24). 
The smaller side chain of Phe56 of Cdc42 favors the bulkier side chains of Leu1941 
and Gln1944 of DOCK9, whereas the larger side chain of Try56 of Rac1 prefers the 
smaller side chains of Met1529 and Asn1532 of DOCK2 (or Met1524 and Asn1527 of 
DOCK1). Therefore, substitution of Phe56 of Cdc42 with tryptophan should cause 
steric hindrance in the pocket of DOCK9, while substitution of Try56 of Rac1 with 
phenylalanine should make less contact with DOCK2 or DOCK1. How can DOCK7 
recognize both Cdc42 and Rac1? DOCK7 combines Met1875 from the DOCK-A 
subfamily and Gln1878 from the DOCK-D subfamily at the corresponding positions, 
which still make enough contact with phenylalanine of Cdc42, but can not cause 
significant steric hindrance with tryptophan of Rac1. By this “compromise” strategy, 
DOCK7 is capable of the dual recognition of both Cdc42 and Rac1 at the cost of 
specificity. Therefore, the M1875L and Q1978N mutants of DOCK7 exhibit 
specificity toward Cdc42 and Rac1, respectively (Fig. 5.4C). 
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 Previously, Wu et al. defined a limit C-terminal region (designated as DHR2c) 
of the DHR2 domain of DOCK1, which showed full GEF activity (24). Here I also 
showed that DOCK7 possessed a similar DHR2c portion which exhibited the same 
catalytic activity as DHR2s (Fig. 5.3A). Although the N-terminus of DOCK9 DHR2 
contributed slightly, it appears that all the DOCK180-related members have this 
smaller domain which is necessary and sufficient to activate its cognate GTPases. 
However, in contrast to DHR2c, the longer DHR2s of DOCK7 preferentially binds to 
the active forms of GTPases, which suggests the potential for positive cooperativity 
through the ability of activated GTPases to recuit the GEF to the liposome surface 
(Fig. 5.7). Similarly, the PH domain of PDZ-RhoGEF has been demonstrated to bind 
the active form of RhoA at the effector binding site. (44). Additionally, the DH-PH 
domain of PDZ-RhoGEF can form a ternary complex with the active form of RhoA 
throught the PH domain, while the inactive form of RhoA binds to the DH domain. 
However, activated RhoA does not appear to affect the GEF activity of PDZ-RhoGEF 
in vitro. It is possible that, in order to enhance the accessibility of GEFs, cells take this 
regulatory strategy to recruit GEFs to membranes. For example, the PH domain of 
Arno, an Arf1 GEF, binds to myristoylated Arf6 on the liposomes in vitro, which in 
turn increases the GEF activity of Arno, forming a positive feedback loop (45). Lin et 
al. found that the active form of Cdc42 interacted with the N-terminus and release the 
autoinhibition of the full length DOCK11, leading to the positive feedback activation 
of Cdc42 (46). Therefore, it is possible that DOCK180 family members recruit the 
active form of their coupling GTPases to modulate the spatial and temporal regulation 
of their GEF activity.    
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Chapter 6 
Conclusions and Future Directions 
6.1 Conclusions 
My thesis research has involved structure-function studies of members of the sirtuin 
family, and biochemical characterization of the Cdc42/Rac-activator DOCK7. Below, 
I will briefly summarize the main highlights from each of these lines of study and then 
put forward some interesting considerations for future work.  
Human SIRT5 is an NAD-dependent demalonylase and desuccinylase. SIRT5 
has been reported to have weak deacetylase activity (1). Co-crystallization of SIRT5 
with acetylated peptides failed to produce any crystals amenable for X-ray diffraction. 
However, the thioacetylated peptides were successfully co-crystallized with SIRT5. 
The X-ray crystal structure of SIRT5 in complex with thioacetyl H3K9 peptide and a 
buffer molecule CHES showed that SIRT5 harbored a larger acyl binding pocket with 
two non-hydrophobic residues, Tyr102 and Arg105, at the bottom of the pocket. The 
unique features of SIRT5’s acyl binding pocket and the binding of CHES inspired us 
and led to the discovery of the novel functions of SIRT5. Now we believe that SIRT5 
is a demalonylase and desuccinylase with robust activity, comparable to the 
deacetylase activity of SIRT1. As expected, the succinyl group of the H3K9 peptide 
interacts with Tyr102 and Arg105 of SIRT5, such that mutating either of these two 
residues dramatically decreases the enzymatic activity. Furthermore, using mass 
spectrometry, a number of mitochondrial proteins have been identified to be 
malonylated and succinylated. Some of the lysine residues of proteins can be both 
acetylated and succinylated. Finally, SIRT5 modulates the enzymatic activity of 
carbamoyl phosphate synthetase 1 (CPS1) by catalyzing its desuccinylation at lysine 
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1291.   
The mechanism of SIRT5’s desuccinylation is similar to that used by other 
sirtuins to catalyze deacetylation. To delineate the mechanism of desuccinylation, I 
have solved a series of SIRT5 complex structures, including the complexes of SIRT5-
succinyl H3K9 peptide, SIRT5-succinyl H3K9 peptide-NAD, and SIRT5-S-bicyclic 
intermediate, representing the substrate binding step, the Michaelis-Menten complex 
step, and the intermediate II step, respectively. The 1’,2’-bicyclic intermediate 
complex structure supports the peptidyl-ADPR-amidate mechanism. This is the first 
time that a bicyclic intermediate was directly observed in an X-ray crystal structure. 
This intermediate was obtained by co-crystallizing SIRT5 with its specific inhibitor, 
the thiosuccinyl H3K9 peptide, followed by soaking in NAD in the time range of 0.5-
16 hours. I was unable to obtain the alkylamidate intermediate I, which suggested that 
the inhibition mechanism of thiosuccinyl peptide may be that the S-1’,2’-bicyclic 
intermediate was stalled at the active site of SIRT5. 
Plasmodium falciparum Sir2A (PfSir2A) preferentially removes the medium 
and long chain fatty acyl modifications from lysine residues. PfSir2A has been shown 
to have weak deacetylase activity (2). We found that PfSir2A was more efficient in the 
hydrolysis of the medium and long chain (C8-C14) fatty acyl groups attached to 
lysine. The crystal structures of PfSir2A in complex with the myristoyl H3K9 peptide 
or with both peptide and NAD uncovered the structural features of PfSir2A which 
explained PfSir2A’s capability of catalyzing the deacylation of medium and long 
chain fatty acyl groups from lysine. PfSir2A possesses a long open hydrophobic acyl 
binding tunnel which accommodates the myristoyl group. Additionally, modifications 
leading to the incorporation of the medium and long chain fatty acids were reported to 
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occur in the parasite P. falciparum. 
Prenylation and membrane localization of Cdc42/Rac1 are essential for the 
activation by DOCK7. No robust GEF activity of DOCK7 has been reported towards 
either Cdc42 or Rac1 (3, 4). In Chapter 5 of my thesis, I show that DOCK7 is unable 
to stimulate the activation of non-prenylated Cdc42/Rac1 in solution. However, the 
activation of prenylated Cdc42/Rac1 can be catalyzed by DOCK7 in model liposomes. 
The combination of methionine and glutamine in the α10 helix of DOCK7 
enables it to dually recongnize Cdc42 and Rac1. Position 56 of Cdc42 and Rac1 (i.e. 
Phe56 in Cdc42 and Trp56 in Rac1) has been shown to be the key site for the specific 
recognition by their cognate GEFs (5, 6). The X-ray crystal structures of two 
complexes (Cdc42-DOCK9 and Rac1-DOCK2 complexes) have revealed that two 
residues in the α10 helix of DOCK proteins, leucine and glutamine in DOCK9, and 
methionine and asparagine in DOCK2, interact with Phe56 of Cdc42 and Trp56 of 
Rac1, respectively (6, 7). DOCK7 combines methionine and glutamine at the 
corresponding positions, allowing it to exhibit dual GEF activity on Cdc42 and Rac1. 
Replacing methionine with leucine, or glutamine with asparagine, in DOCK7 can 
cause it to become a Cdc42-specific or Rac1-specific GEF, respectively.  
The N-terminus of DOCK7-DHR2s possesses a distal site for the binding of the 
active forms of Cdc42/Rac1. The results of liposome spin-down assays indicate that 
DOCK7 possesses an allosteric site which preferentially binds to the active forms of 
Cdc42/Rac1. This atypical GTPase-GEF binding interaction allows for a possible 
positive feedback activation of these GTPases by DOCK7. 
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6.2 Future Directions 
Studies of the sirtuins- SIRT5, together with SIRT3 and SIRT4, are the three 
mammalian sirtuins which predominantly reside in the mitochondria (8). SIRT3 has 
been demonstrated to regulate cellular metabolism by deacetylating a number of 
metabolic enzymes, including Acetyl-CoA synthetase 2 (ACS2) (9), 3-hydroxyl-3-
methylglutary CoA synthetase 2 (HMGCS2) (10), long-chain acyl CoA 
dehydrogenase (LCAD) (11), glutamate dehydrogenase (GDH), and isocitrate 
dehydrogenase 2 (ICDH2) (12). Very few proteins have been identified as substrates 
of SIRT5. Recently, SIRT5 has been shown to modulate the enzymatic activity of 
CPS1 to regulate the disposal of ammonium which is a product of glutamine 
metabolism, suggesting an important role of SIRT5 in energy metabolism (13). 
Therefore, future identification of the physiological substrates of SIRT5 should 
provide interesting insights into its cellular functions.  
SIRT5 is the only mammalian sirtuin with demalonylse and desuccinylase 
activities. This unique feature enables us to design SIRT5-specific inhibitors, 
including thiosuccinyl lysine peptide with an IC50 in the micromolar scale (Bin He, 
unpublished data). The thiosuccinyl peptide forms a bicyclic intermediate which is 
stalled at the active site of SIRT5, thereby decreasing the turnover rate of the product. 
The structure of SIRT5 bound to this intermediate will provide insights into the 
optimization of SIRT5-specific inhibitors. Because SIRT5 has been shown in our 
laboratory to be essential for the growth of different cancer cell lines (Bo Li, 
unpublished data), the design of specific SIRT5 inhibitors must have therapeutic 
applications.  
Given that metabolic changes are key features of cancer cells (14), it will be of 
  - 178 -
interest to further investigate the role that SIRT5 plays in tumorigenesis, and in 
particular, to identify the relevant substrates for SIRT5 in cancer cells as well as 
possible regulators of its enzymatic activity.  
Similar to the case of SIRT5, the complex structures of PfSir2A will facilitate 
the development of PfSir2A-specific inhibitors, which show great potential in treating 
malaria. PfSir2A has been reported to control the exclusive expression of cell surface 
antigens to avoid the clean-up by the host immune surveillance, and Plasmodium 
falciparum is an exceedingly dangerous species that is responsible for 90% of the 
deaths arising from malaria (15, 16).  
Studies of DOCK7- DOCK7 binds to both inactive and active forms of 
prenylated Cdc42/Rac1. However, an important question concerns the identity of the 
regions in DOCK7 that interact with the inactive and active forms of the GTPases. 
Two alternative methods can be used to answer this question. Biochemically, a series 
of truncation constructs of the limit functional domain of DOCK7 (i.e. DHR2s) can be 
cloned, expressed, and purified to test their ability to bind to the GTPases. This 
method should allow the mapping of the binding site for the inactive and acive forms 
of the GTPases. Structurally, the Cdc42·GTPγS-DHR2s-Cdc42·GDP (or 
Rac1·GTPγS-DHR2s-Rac1·GDP) complex can be obtained by mixing the purified 
GTPase and DHR2s recombinant proteins, and further purified for crystallization. The 
crystal structure would provide important information regarding how DOCK7-DHR2s 
can bind both forms of the GTPase. 
All of the characterizations of DOCK7 in Chapter 5 of my thesis were 
performed using either DHR2s or DHR2c. Considering that the full length DOCK7 
harbors a DHR1 domain in the N-terminus as well as the linker between DHR1 and 
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DHR2, it is likely that the other parts of the protein beyond DHR2 will affect the GEF 
activity of DOCK7. For example, the N-terminus of DOCK11 mediates a positive 
feedback in activating Cdc42. Thus, it should be interesting to perform biochemical 
characterizations of the GEF activity for the full length DOCK7, both using in vitro 
liposome system, as well as ultimately in cells.  
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